Author: "Forsea, A.-M." - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Forsea, A.-M."' showing total 50 results

Start Over Author "Forsea, A.-M."

50 results on '"Forsea, A.-M."'

1. RESCUE STUDY – International Survey on training of Dermatology Residents in Supportive Oncodermatology

Author: Ortiz Brugués, A., primary, Apalla, Z., additional, Nikolaou, V., additional, Freites-Martinez, A., additional, Anadkat, M., additional, Bang, A., additional, Elshot, Y., additional, Forsea, A.-M., additional, Pagès, C., additional, Guillon, B., additional, Lacroix, N., additional, Boileau, M., additional, Fattore, D., additional, Lacouture, M., additional, and Sibaud, V., additional
Published: 2024
Full Text: View/download PDF

2. A-271 - RESCUE STUDY – International Survey on training of Dermatology Residents in Supportive Oncodermatology

Author: Ortiz Brugués, A., Apalla, Z., Nikolaou, V., Freites-Martinez, A., Anadkat, M., Bang, A., Elshot, Y., Forsea, A.-M., Pagès, C., Guillon, B., Lacroix, N., Boileau, M., Fattore, D., Lacouture, M., and Sibaud, V.
Published: 2024
Full Text: View/download PDF

3. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments

Author: Kandolf Sekulovic, L., Peris, K., Hauschild, A., Stratigos, A., Grob, J.-J., Nathan, P., Dummer, R., Forsea, A.-M., Hoeller, C., Gogas, H., Demidov, L., Lebbe, C., Blank, C., Olah, J., Bastholt, L., Herceg, D., Neyns, B., Vieira, R., Hansson, J., Rutkowski, P., Krajsova, I., Bylaite-Bucinskiene, M., Zalaudek, I., Maric-Brozic, J., Babovic, N., Banjin, M., Putnik, K., Weinlich, G., Todorovic, V., Kirov, K., Ocvirk, J., Zhukavets, A., Kukushkina, M., De La Cruz Merino, L., Ymeri, A., Risteski, M., and Garbe, C.
Published: 2017
Full Text: View/download PDF

4. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022

Author: Gauci, Marie-Léa, Aristei, Cynthia, Becker, Jurgen C, Blom, Astrid, Bataille, Veronique, Dreno, Brigitte, Del Marmol, Veronique, Forsea, Ana M, Fargnoli, Maria C, Grob, Jean-Jacques, Gomes, Fabio, Hauschild, Axel, Hoeller, Christoph, Harwood, Catherine, Kelleners-Smeets, Nicole, Kaufmann, Roland, Lallas, Aimilios, Malvehy, Josep, Moreno-Ramirez, David, Peris, Ketty, Pellacani, Giovanni, Saiag, Philippe, Stratigos, Alexander J, Vieira, Ricardo, Zalaudek, Iris, van Akkooi, Alexander C J, Lorigan, Paul, Garbe, Claus, Lebbé, Céleste, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Università degli Studi di Perugia = University of Perugia (UNIPG), German Cancer Consortium [Heidelberg] (DKTK), Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Hôpital Ambroise Paré [AP-HP], Mount Vernon Cancer Centre [Northwood, UK] (MV2C), Mount Vernon Cancer Centre, Nantes Université (Nantes Univ), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Université libre de Bruxelles (ULB), University Emergency Hospital [Bucharest], University of L'Aquila [Italy] (UNIVAQ), Aix Marseille Université (AMU), Assistance Publique - Hôpitaux de Marseille (APHM), University of Manchester [Manchester], University Hospital Schleswig-Holstein [Kiel, Germany], Medizinische Universität Wien = Medical University of Vienna, Queen Mary University of London (QMUL), Maastricht University [Maastricht], Frankfurt University Hospital, Aristotle University of Thessaloniki, University of Barcelona, Hospital Universitario Virgen Macarena [Séville], Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia (UNIMORE), National and Kapodistrian University of Athens (NKUA), Coimbra Hospital and Universitary Centre [Coimbra, Portugal] (CHUC), Università degli studi di Trieste = University of Trieste, Antoni van Leeuwenhoek Hospital, Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Roche, AbbVie, Genesis Pharma, J.C. Becker reports receiving speaker’s bureau honoraria from Amgen, Pfizer, Recordati and Sanofi, is a paid consultant/advisory board member/DSMB member for Almirall, Boehringer Ingelheim, InProTher, ICON, MerckSerono, Pfizer, 4SC, and Sanofi/Regeneron. His group receives research grants from Bristol-Myers Squibb, Merck Serono, HTG, IQVIA, and Alcedis., Speaker’s bureau honoraria from Amgen, Pfizer, Recordati and Sanofi, paid consultant/advisory/DSMB board member for Almirall, Boehringer Ingelheim, ICON, InProTher, MerckSerono, Pfizer, 4SC, and Sanofi/Regeneron. Research grants from Bristol-Myers Squibb, Merck Serono, HTG, IQVIA, and Alcedis., Gauci, Marie-Léa, Aristei, Cynthia, Becker, Jurgen C, Blom, Astrid, Bataille, Veronique, Dreno, Brigitte, Del Marmol, Veronique, Forsea, Ana M, Fargnoli, Maria C, Grob, Jean-Jacque, Gomes, Fabio, Hauschild, Axel, Hoeller, Christoph, Harwood, Catherine, Kelleners-Smeets, Nicole, Kaufmann, Roland, Lallas, Aimilio, Malvehy, Josep, Moreno-Ramirez, David, Peris, Ketty, Pellacani, Giovanni, Saiag, Philippe, Stratigos, Alexander J, Vieira, Ricardo, Zalaudek, Iri, van Akkooi, Alexander C J, Lorigan, Paul, Garbe, Clau, and Lebbé, Céleste
Subjects: Male, Cancer Research, Skin Neoplasms, Consensus, Consensu, HIV Infections/complications, HIV Infections, [SDV.CAN]Life Sciences [q-bio]/Cancer, Guideline, Guidelines, Sentinel Lymph Node Biopsy/adverse effects, Merkel Cell/diagnosis, Humans, HIV Infection, Skin Neoplasms/diagnosis, Neoplasm Staging, MCC, Merkel cell, Manchester Cancer Research Centre, Sentinel Lymph Node Biopsy, ResearchInstitutes_Networks_Beacons/mcrc, Carcinoma, Carcinoma, Merkel Cell, EDF, Oncology, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Human
Abstract: International audience; Merkel cell carcinoma (MCC) is a rare skin cancer, accounting for less than 1% of all cutaneous malignancies. It is found predominantly in white populations and risk factors include advanced age, ultraviolet exposure, male sex, immunosuppression, such as AIDS/HIV infection, haematological malignancies or solid organ transplantation, and Merkel cell polyomavirus infection. MCC is an aggressive tumour with 26% of cases presenting lymph node involvement at diagnosis and 8% with distant metastases. Five-year overall survival rates range between 48% and 63%. Two subsets of MCC have been characterised with distinct molecular pathogenetic pathways: ultraviolet-induced MCC versus virus-positive MCC, which carries a better prognosis. In both subtypes, there are alterations in the retinoblastoma protein and p53 gene structure and function. MCC typically manifests as a red nodule or plaque with fast growth, most commonly on sun exposed areas. Histopathology (small-cell neuroendocrine appearance) and immunohistochemistry (CK20 positivity and TTF-1 negativity) confirm the diagnosis. The current staging systems are the American Joint Committee on Cancer/Union for international Cancer control 8th edition. Baseline whole body imaging is encouraged to rule out regional and distant metastasis. For localised MCC, first-line treatment is surgical excision with postoperative margin assessment followed by adjuvant radiation therapy (RT). Sentinel lymph node biopsy is recommended in all patients with MCC without clinically detectable lymph nodes or distant metastasis. Adjuvant RT alone, eventually combined with complete lymph nodes dissection is proposed in case of micrometastatic nodal involvement. In case of macroscopic nodal involvement, the standard of care is complete lymph nodes dissection potentially followed by post-operative RT. Immunotherapy with anti-PD-(L)1 antibodies should be offered as first-line systemic treatment in advanced MCC. Chemotherapy can be used when patients fail to respond or are intolerant for anti-PD-(L)1 immunotherapy or clinical trials.
Published: 2022

5. A Novel Approach in Melanoma Identification

Author: Oprea, A. E., Strungaru, R., Forsea, A. M., Ungureanu, G. M., Magjarevic, R., editor, Nagel, J. H., editor, Vander Sloten, Jos, editor, Verdonck, Pascal, editor, Nyssen, Marc, editor, and Haueisen, Jens, editor
Published: 2009
Full Text: View/download PDF

6. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022

Author: Garbe, C. Amaral, T. Peris, K. Hauschild, A. Arenberger, P. Basset-Seguin, N. Bastholt, L. Bataille, V. del Marmol, V. Dréno, B. Fargnoli, M.C. Forsea, A.-M. Grob, J.-J. Höller, C. Kaufmann, R. Kelleners-Smeets, N. Lallas, A. Lebbé, C. Lytvynenko, B. Malvehy, J. Moreno-Ramirez, D. Nathan, P. Pellacani, G. Saiag, P. Stratigos, A.J. Van Akkooi, A.C.J. Vieira, R. Zalaudek, I. Lorigan, P. European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), the European Organization for Research Treatment of Cancer (EORTC)
Abstract: Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. The diagnosis of melanoma can be made clinically and shall always be confirmed with dermatoscopy. If a melanoma is suspected, a histopathological examination is always required. Sequential digital dermatoscopy and full body photography can be used in high-risk patients to improve the detection of early melanoma. Where available, confocal reflectance microscopy can also improve clinical diagnosis in special cases. Melanoma shall be classified according to the 8th version of the American Joint Committee on Cancer classification. Thin melanomas up to 0.8 mm tumor thickness do not require further imaging diagnostics. From stage IB onwards, examinations with lymph node sonography are recommended, but no further imaging examinations. From stage IIC onwards whole-body examinations with computed tomography (CT) or positron emission tomography CT (PET-CT) in combination with brain magnetic resonance imaging are recommended. From stage III and higher, mutation testing is recommended, particularly for BRAF V600 mutation. It is important to provide a structured follow-up to detect relapses and secondary primary melanomas as early as possible. There is no evidence to define the frequency and extent of examinations. A stage-based follow-up scheme is proposed which, according to the experience of the guideline group, covers the optimal requirements, but further studies may be considered. This guideline is valid until the end of 2024. © 2022 Elsevier Ltd
Published: 2022

7. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment

Author: Stratigos, Alexander J, Garbe, Claus, Dessinioti, Clio, Lebbe, Celeste, Bataille, Veronique, Bastholt, Lars, Dreno, Brigitte, Concetta Fargnoli, Maria, Forsea, Ana M, Frenard, Cecille, Harwood, Catherine A, Hauschild, Axel, Hoeller, Christoph, Kandolf-Sekulovic, Lidija, Kaufmann, Roland, Kelleners-Smeets, Nicole W J, Malvehy, Josep, Del Marmol, Veronique, Middleton, Mark R, Moreno-Ramirez, David, Pellecani, Giovanni, Peris, Ketty, Saiag, Philippe, van den Beuken-van Everdingen, Marieke H J, Vieira, Ricardo, Zalaudek, Iris, Eggermont, Alexander M M, Grob, Jean-Jacques, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC), HAL UVSQ, Équipe, National and Kapodistrian University of Athens (NKUA), Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), North & East Hertfordshire NHS Trust [Northwood, UK], Odense University Hospital (OUH), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), University of L'Aquila [Italy] (UNIVAQ), University of Bucharest (UniBuc), Queen Mary University of London (QMUL), Kiel University, Medizinische Universität Wien = Medical University of Vienna, Military Medical Academy [Belgrade, Serbia] (2MA), Frankfurt University Hospital, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), CIBER de Enfermedades Raras (CIBERER), Université libre de Bruxelles (ULB), University of Oxford, Hospital Universitario Virgen Macarena [Sevilla, Spain] (HUVM), Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia (UNIMORE), Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Hôpital Ambroise Paré [AP-HP], Coimbra Hospital and Universitary Centre [Coimbra, Portugal] (CHUC), Università degli studi di Trieste = University of Trieste, Princess Máxima Center for Pediatric Oncology, Aix Marseille Université (AMU), Assistance Publique - Hôpitaux de Marseille (APHM), Amgen Bristol-Myers Squibb, BMS Pfizer AstraZeneca GlaxoSmithKline, GSK Merck Novartis Roche Sanofi AbbVie Meso Scale Diagnostics, MSD Merck Sharp and Dohme, MSD DUSA Pharmaceuticals Les Laboratories Pierre Fabre Cilag LEO Pharma Research Foundation, The development of the current set of guideline was supported solely by funds of the EADO which were used to mainly support the consensus meeting.Dr. Stratigos reports personal fees and/or research support from Novartis, Roche, BMS, AbbVie, Sanofi, Regeneron, Genesis Pharma, outside the submitted work. Dr. Garbe reports personal fees from Amgen, personal fees from MSD, grants and personal fees from Novartis, grants and personal fees from NeraCare, grants and personal fees from BMS, personal fees from Pierre Fabre, personal fees from Philogen, grants and personal fees from Roche, grants and personal fees from Sanofi, outside the submitted work. Dr. Dessinioti has nothing to disclose. Dr. Lebbe reports grants and personal fees from Bristol-Myers Squibb, personal fees from MSD, personal fees from Novartis, personal fees from Amgen, grants and personal fees from Roche, personal fees from Avantis Medical Systems, personal fees from Pierre Fabre, personal fees from Pfizer, personal fees from Incyte, outside the submitted work. Dr. Bataille reports personal fees from Novartis, personal fees from Merck MSD, outside the submitted work. Dr. Bastholt reports personal fees for advisory board activity: BMS, Roche, Novartis, Pierre Fabre, AstraZeneca, Incyte, MSD/Merck, Bayer. Dr. Dr?no reports grants and personal fees from BMS, personal fees from MSD, grants and personal fees from Roche, grants and personal fees from Fabre, grants and personal fees from Sanofi, outside the submitted work. Dr. Fargnoli reports grants and personal fees from Almirall, grants and personal fees from Leo Pharma, personal fees from Janssen, grants and personal fees from Novartis, personal fees from Lilly, grants and personal fees from Sanofi, personal fees from UCB, grants and personal fees from AbbVie, personal fees from Celgene, personal fees from Pierre Fabre, grants and personal fees from Galderma, personal fees from Mylan, personal fees from Medac Pharma, personal fees from Roche, personal fees from Sun Pharma, outside the submitted work. Dr. Forsea reports scientific consultant/speaker fee from Novartis, Leo Pharma, Solartium, Pierre Fabre, outside the submitted work. Dr. Frenard has nothing to disclose. Dr. Harwood reports institutional research grants and honoraria from Sanofi, Novartis, Merck, Pfizer, Galderma, Meda, Almirall, PellePharm, Leo Pharma, Ceries. Dr. Hauschild reports honoraria and/or research grants from Almirall, BMS, Roche, Novartis, Pierre Fabre, Sun Pharma, Merck Serono, Sanofi-Aventis, Regeneron, MSD/Merck, Philogen, OncoSec outside the submitted work. Dr. Hoeller reports grants and personal fees from Amgen, personal fees from BMS, personal fees from MSD, personal fees from Novartis, personal fees from Pierre Fabre, personal fees from Roche, personal fees from Sanofi, personal fees from Incyte, outside the submitted work. Dr. Kandolf-Sekulovic reports speakers? honoraria for Roche, Novartis, MSD, BMS, Janssen outside the submitted work. Dr. Kaufmann reports institutional research grants (clinical trials) from AbbVie, Amgen, Biontech, BMS, Celgene, Galderma, Janssen, Leo, Lilly, Merck, MSD, Novartis, Pierre Fabre, Pfizer, Regeneron, Roche, Wyeth. Advisory board and honoraria from Merz, Roche, Novartis. Dr. Kelleners-Smeets reports grants from Netherlands Organization for Health Research and Development, other from Janssen-Cilag, other from AbbVie, other from Galderma, outside the submitted work. Dr. Malvehy reports research grants from Almirall, ISDIN, Leo Pharma, Galderma, GSK, Cantabria, participation in advisory board meetings for Almirall, Sun Pharma, BMS, Roche, Novartis, Pierre Fabre. Dr. del Marmol reports personal fees from MSD, from BMS, personal fees from Sanofi, grants and personal fees from AbbVie, grants from Janssen, outside the submitted work. Dr. Middleton reports personal fees and/or grants from Amgen, Roche, AstraZeneca, GSK, Novartis, Immunocore, BMS, Eisai and Merck. Institutional funding from Millennium, Vertex, Pfizer, Regeneron, TC Biopharm, BioLineRx, Replimune, outside the submitted work. Dr. Moreno-Ram?rez has nothing to disclose. Dr. Pellecani reports grants from university of Modena and Reggio Emilia, during the conduct of the study, grants from Novartis, grants and personal fees from Almirall, grants from Leo Pharma, from null, outside the submitted work. Dr. Peris reports honoraria for advisory board and grants from AbbVie, Almirall, Biogen Celgene, Lilly, Galderma, Leo Pharma, Novartis, Roche, Sanofi, Sun Pharma, Sandoz outside the submitted work. Dr. Saiag reports honoraria for advisory board and grants from Amgen, Bristol-Myers Squibb, MSD, Merck Serono, Novartis, Pfizer, Roche-Genentech, Pierre Fabre, and Sanofi, outside the submitted work. Dr. van den Beuken-van Everdingen has nothing to disclose. Dr. Vieira has nothing to disclose. Dr. Zalaudek reports honoraria and advisory board and grants from Sanofi, Sun Pharma, Novartis, Galderma, Roche, Celgene, Almirall, Leo Pharma, Mylan, Difa Cooper, Cieffe Labs, La Roche Posay, Pierre Fabre. Dr. Eggermont reports over the last 5 years personal fees as a consultant advisor for BIOCAD, BioInvent, Bristol-Myers Squibb (BMS), CatalYm, Ellipses, GlaxoSmithKline (GSK), HalioDx, Incyte, IO Biotech, ISA Pharmaceuticals, Merck Sharpe & Dohme (MSD), Novartis, Pfizer, Polynoma, Regeneron, Sanofi, SELLAS, SkylineDx. Dr. Grob reports personal fees for advisory board and as speaker from Amgen, Roche, GSK, Novartis, BMS, Pierre Fabre, Merck, Sanofi, Merck, Pfizer outside the submitted work., Dr. Stratigos reports personal fees and/or research support from Novartis, Roche, BMS, AbbVie, Sanofi, Regeneron, Genesis Pharma, outside the submitted work. Dr. Garbe reports personal fees from Amgen, personal fees from MSD, grants and personal fees from Novartis , grants and personal fees from NeraCare , grants and personal fees from BMS , personal fees from Pierre Fabre, personal fees from Philogen, grants and personal fees from Roche , grants and personal fees from Sanofi , outside the submitted work. Dr. Dessinioti has nothing to disclose. Dr. Lebbe reports grants and personal fees from Bristol-Myers Squibb , personal fees from MSD, personal fees from Novartis, personal fees from Amgen, grants and personal fees from Roche , personal fees from Avantis Medical Systems, personal fees from Pierre Fabre, personal fees from Pfizer, personal fees from Incyte, outside the submitted work. Dr. Bataille reports personal fees from Novartis, personal fees from Merck MSD, outside the submitted work. Dr. Bastholt reports personal fees for advisory board activity: BMS, Roche, Novartis, Pierre Fabre, AstraZeneca, Incyte, MSD/Merck, Bayer. Dr. Dréno reports grants and personal fees from BMS , personal fees from MSD, grants and personal fees from Roche , grants and personal fees from Fabre , grants and personal fees from Sanofi , outside the submitted work. Dr. Fargnoli reports grants and personal fees from Almirall , grants and personal fees from Leo Pharma , personal fees from Janssen, grants and personal fees from Novartis , personal fees from Lilly, grants and personal fees from Sanofi , personal fees from UCB, grants and personal fees from AbbVie , personal fees from Celgene, personal fees from Pierre Fabre, grants and personal fees from Galderma , personal fees from Mylan, personal fees from Medac Pharma, personal fees from Roche, personal fees from Sun Pharma, outside the submitted work. Dr. Forsea reports scientific consultant/speaker fee from Novartis, Leo Pharma, Solartium, Pierre Fabre, outside the submitted work. Dr. Frenard has nothing to disclose. Dr. Harwood reports institutional research grants and honoraria from Sanofi , Novartis , Merck , Pfizer , Galderma , Meda , Almirall , PellePharm , Leo Pharma , Ceries . Dr. Hauschild reports honoraria and/or research grants from Almirall , BMS , Roche , Novartis , Pierre Fabre , Sun Pharma , Merck Serono , Sanofi-Aventis , Regeneron , MSD/Merck , Philogen , OncoSec outside the submitted work. Dr. Hoeller reports grants and personal fees from Amgen , personal fees from BMS, personal fees from MSD, personal fees from Novartis, personal fees from Pierre Fabre, personal fees from Roche, personal fees from Sanofi, personal fees from Incyte, outside the submitted work. Dr. Kandolf-Sekulovic reports speakers’ honoraria for Roche, Novartis, MSD, BMS, Janssen outside the submitted work. Dr. Kaufmann reports institutional research grants (clinical trials) from AbbVie , Amgen , Biontech , BMS , Celgene , Galderma , Janssen , Leo , Lilly , Merck , MSD , Novartis , Pierre Fabre , Pfizer , Regeneron , Roche , Wyeth . Advisory board and honoraria from Merz, Roche, Novartis. Dr. Kelleners-Smeets reports grants from Netherlands Organization for Health Research and Development , other from Janssen-Cilag, other from AbbVie, other from Galderma, outside the submitted work. Dr. Malvehy reports research grants from Almirall , ISDIN , Leo Pharma , Galderma , GSK , Cantabria, participation in advisory board meetings for Almirall, Sun Pharma, BMS, Roche, Novartis, Pierre Fabre. Dr. del Marmol reports personal fees from MSD, from BMS, personal fees from Sanofi, grants and personal fees from AbbVie, grants from Janssen , outside the submitted work. Dr. Middleton reports personal fees and/or grants from Amgen , Roche , AstraZeneca , GSK , Novartis , Immunocore , BMS , Eisai and Merck . Institutional funding from Millennium , Vertex , Pfizer , Regeneron , TC Biopharm , BioLineRx , Replimune , outside the submitted work. Dr. Moreno-Ramírez has nothing to disclose. Dr. Pellecani reports grants from university of Modena and Reggio Emilia , during the conduct of the study, grants from Novartis , grants and personal fees from Almirall , grants from Leo Pharma , from null, outside the submitted work. Dr. Peris reports honoraria for advisory board and grants from AbbVie , Almirall , Biogen Celgene , Lilly , Galderma , Leo Pharma , Novartis , Roche , Sanofi , Sun Pharma , Sandoz outside the submitted work. Dr. Saiag reports honoraria for advisory board and grants from Amgen , Bristol-Myers Squibb , MSD , Merck Serono , Novartis , Pfizer , Roche-Genentech , Pierre Fabre , and Sanofi , outside the submitted work. Dr. van den Beuken-van Everdingen has nothing to disclose. Dr. Vieira has nothing to disclose. Dr. Zalaudek reports honoraria and advisory board and grants from Sanofi , Sun Pharma , Novartis , Galderma , Roche , Celgene , Almirall , Leo Pharma , Mylan , Difa Cooper , Cieffe Labs , La Roche Posay , Pierre Fabre . Dr. Eggermont reports over the last 5 years personal fees as a consultant advisor for BIOCAD, BioInvent, Bristol-Myers Squibb (BMS), CatalYm, Ellipses, GlaxoSmithKline (GSK), HalioDx, Incyte, IO Biotech, ISA Pharmaceuticals, Merck Sharpe & Dohme (MSD), Novartis, Pfizer, Polynoma, Regeneron, Sanofi, SELLAS, SkylineDx. Dr. Grob reports personal fees for advisory board and as speaker from Amgen, Roche, GSK, Novartis, BMS, Pierre Fabre, Merck, Sanofi, Merck, Pfizer outside the submitted work., European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC), Stratigos, A. J., Garbe, C., Dessinioti, C., Lebbe, C., Bataille, V., Bastholt, L., Dreno, B., Concetta Fargnoli, M., Forsea, A. M., Frenard, C., Harwood, C. A., Hauschild, A., Hoeller, C., Kandolf-Sekulovic, L., Kaufmann, R., Kelleners-Smeets, N. W. J., Malvehy, J., del Marmol, V., Middleton, M. R., Moreno-Ramirez, D., Pellecani, G., Peris, K., Saiag, P., van den Beuken-van Everdingen, M. H. J., Vieira, R., Zalaudek, I., Eggermont, A. M. M., Grob, J. -J., Dermatologie, MUMC+: MA Dermatologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, RS: MHeNs - R3 - Neuroscience, Anesthesiologie, MUMC+: MA Anesthesiologie (9), and MUMC+: TPZ Palliatieve Zorg (9)
Subjects: 0301 basic medicine, Oncology, Cancer Research, Skin Neoplasms, medicine.medical_treatment, Dermatologic Surgical Procedures, Aftercare, Anti-PD-1 antibody, Cemiplimab, Chemotherapy, Cutaneous squamous cell carcinoma, EGFR inhibitors, Follow-up, Locally advanced, Metastatic, Radiotherapy, Surgical excision, Treatment, Medical Oncology, Metastasis, METASTATIC CUTANEOUS HEAD, 0302 clinical medicine, Antineoplastic Agents, Immunological, Quality of life, IN-TRANSIT METASTASIS, Monoclonal, ADJUVANT RADIOTHERAPY, Lymph node, Humanized, Societies, Medical, Skin, Cetuximab, Palliative Care, Margins of Excision, Chemoradiotherapy, 3. Good health, EGFR inhibitor, Dissection, medicine.anatomical_structure, Immunological, 030220 oncology & carcinogenesis, PHASE-II, Carcinoma, Squamous Cell, Sunlight, Settore MED/35 - MALATTIE CUTANEE E VENEREE, medicine.drug, medicine.medical_specialty, Consensus, Clinical Decision-Making, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antineoplastic Agents, CERVICAL LYMPH-NODES, Dermatology, Antibodies, Monoclonal, Humanized, ELECTIVE NECK DISSECTION, Antibodies, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Patient Education as Topic, Internal medicine, Humans, Lymph Node Excision, Lymph Nodes, Neoplasm Staging, Patient Care Team, Medical, medicine, ORGAN TRANSPLANT RECIPIENTS, business.industry, Carcinoma, Guideline, medicine.disease, Cancérologie, Radiation therapy, 030104 developmental biology, Squamous Cell, INTERFERON-ALPHA, business, GROWTH-FACTOR RECEPTOR, Societies, INTRALESIONAL METHOTREXATE
Abstract: In order to update recommendations on treatment, supportive care, education and follow-up of patients with invasive cutaneous squamous cell carcinoma (cSCC), a multidisciplinary panel of experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization of Research and Treatment of Cancer was formed. Recommendations were based on evidence-based literature review, guidelines and expert consensus. Treatment recommendations are presented for common primary cSCC (low risk, high risk), locally advanced cSCC, regional metastatic cSCC (operable or inoperable) and distant metastatic cSCC. For common primary cSCC (the most frequent cSCC type), first-line treatment is surgical excision with postoperative margin assessment or microscopically controlled sugery. Safety margins containing clinical normal-appearing tissue around the tumour during surgical excision and negative margins as reported in the pathology report are necessary to minimise the risk of local recurrence and metastasis. In case of positive margins, a re-excision shall be done, for operable cases. Lymph node dissection is recommended for cSCC with cytologically or histologically confirmed regional nodal involvement. Radiotherapy should be considered as curative treatment for inoperable cSCC, or for non-surgical candidates. Anti-PD-1 antibodies are the first-line systemic treatment for patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiation, with cemiplimab being the first approved systemic agent for advanced cSCC by the Food and Drug Administration/European Medicines Agency. Second-line systemic treatments for advanced cSCC include epidermal growth factor receptor inhibitors (cetuximab) combined with chemotherapy or radiation therapy. Multidisciplinary board decisions are mandatory for all patients with advanced disease who require more than surgery. Patients should be engaged with informed decisions on management and be provided with best supportive care to optimise symptom management and improve quality of life. Frequency of follow-up visits and investigations for subsequent new cSCC depend on underlying risk characteristics., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2020

8. Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries

Author: Kandolf‐Sekulovic, L, Peris, K, Stratigos, A, Hauschild, A, Forsea, A ‐M, et al, Dummer, R, University of Zurich, and Kandolf‐Sekulovic, L
Subjects: 2708 Dermatology, Infectious Diseases, 10177 Dermatology Clinic, 610 Medicine & health, 2725 Infectious Diseases, Dermatology
Published: 2021

9. Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries

Author: Kandolf-Sekulovic, L., Peris, K., Stratigos, A., Hauschild, A., Forsea, A. M., Lebbe, C., Moreno Ramírez, David, Garbe, C., and Universidad de Sevilla. Departamento de Medicina
Subjects: Europe, Medical disciplines, Melanoma
Abstract: Background and objectives The incidence of melanoma is increasing. This places significant burden on societies to provide efficient cancer care. The European Cancer Organisation recently published the essential requirements for quality melanoma care. The present study is aimed for the first time to roughly estimate the extent to which these requirements have been met in Europe. Materials and methods A web-based survey of experts from melanoma centres in 27 European countries was conducted from 1 February to 1 August 2019. Data on diagnostic techniques, surgical and medical treatment, organization of cancer care and education were collected and correlated with national health and economic indicators and mortality-to-incidence ratio (MIR) as a surrogate for survival. Univariate linear regression analysis was performed to evaluate the correlations. SPSS software was used. Statistical significance was set at P < 0.05. Results The MIR was lower in countries with a high health expenditure per capita and with a higher numbers of general practitioners (GPs) and surgeons (SURG) per million inhabitants. In these countries, GPs and dermatologists (DER) were involved in melanoma detection; high percentage of DER used dermatoscopy and were involved in the follow-up of all melanoma stages; both medical oncologists (ONC) and dermato-oncologists administered systemic treatments; and patients had better access to sentinel lymph node biopsy and were treated within multidisciplinary tumour boards. Conclusion Based on these first estimates, the greater involvement of GPs in melanoma detection; the greater involvement of highly trained DER in dermatoscopy, dermatosurgery, follow-up and the systemic treatment of melanoma; and the provision of ongoing dermato-oncology training for pathologists, SURG, DER and ONC are necessary to provide an optimal melanoma care pathway. A comprehensive analysis of the melanoma care pathway based on clinical melanoma registries will be needed to more accurately evaluate these first insights.
Published: 2021

10. Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries

Author: Kandolf-Sekulovic, L. Peris, K. Stratigos, A. Hauschild, A. Forsea, A.-M. Lebbe, C. Lallas, A. Grob, J.-J. Harwood, C. Gogas, H. Rutkowski, P. Olah, J. Kelleners-Smeets, N.W.J. Paoli, J. Dummer, R. Moreno-Ramirez, D. Bastholt, L. Putnik, K. Karls, R. Hoeller, C. Vandersleyen, V. Vieira, R. Arenberger, P. Bylaite-Buckinskiene, M. Ocvirk, J. Situm, M. Weinlich, G. Banjin, M. Todorovic, V. Ymeri, A. Zhukavets, A. Garbe, C.
Abstract: Background and objectives: The incidence of melanoma is increasing. This places significant burden on societies to provide efficient cancer care. The European Cancer Organisation recently published the essential requirements for quality melanoma care. The present study is aimed for the first time to roughly estimate the extent to which these requirements have been met in Europe. Materials and methods: A web-based survey of experts from melanoma centres in 27 European countries was conducted from 1 February to 1 August 2019. Data on diagnostic techniques, surgical and medical treatment, organization of cancer care and education were collected and correlated with national health and economic indicators and mortality-to-incidence ratio (MIR) as a surrogate for survival. Univariate linear regression analysis was performed to evaluate the correlations. SPSS software was used. Statistical significance was set at P
Published: 2021

11. Melanoma prognosis in Europe: far from equal

Author: Forsea, A. M., del Marmol, V., Stratigos, A., and Geller, A. C.
Published: 2014
Full Text: View/download PDF

12. Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries

Author: Kandolf‐Sekulovic, L., primary, Peris, K., additional, Stratigos, A., additional, Hauschild, A., additional, Forsea, A.‐M., additional, Lebbe, C., additional, Lallas, A., additional, Grob, J.‐J., additional, Harwood, C., additional, Gogas, H., additional, Rutkowski, P., additional, Olah, J., additional, Kelleners‐Smeets, N.W.J., additional, Paoli, J., additional, Dummer, R., additional, Moreno‐Ramirez, D., additional, Bastholt, L., additional, Putnik, K., additional, Karls, R., additional, Hoeller, C., additional, Vandersleyen, V., additional, Vieira, R., additional, Arenberger, P., additional, Bylaite‐Buckinskiene, M., additional, Ocvirk, J., additional, Situm, M., additional, Weinlich, G., additional, Banjin, M., additional, Todorovic, V., additional, Ymeri, A., additional, Zhukavets, A., additional, and Garbe, C., additional
Published: 2021
Full Text: View/download PDF

13. Impact, challenges and perspectives of Euromelanoma, a pan-European campaign of skin cancer prevention

Author: Forsea, A. M. and del Marmol, V.
Published: 2013
Full Text: View/download PDF

14. Inequalities in the patterns of dermoscopy use and training across Europe: conclusions of the Eurodermoscopy pan-European survey

Author: Forsea, A.-M. Tschandl, P. Zalaudek, I. Del Marmol, V. Soyer, H.P. Argenziano, G. Geller, A.C. Arenbergerova, M. Azenha, A. Blum, A. Bowling, J.C. Braun, R.P. Bylaite-Bucinskiene, M. Čabrijan, L. Dobrev, H. Helppikangas, H. Karls, R. Krumkachou, U. Kukutsch, N. McCormack, I. Mekokishvili, L. Nathansohn, N. Nielsen, K. Olah, J. Özdemir, F. Puig, S. Rubegni, P. Rucigaj, T.P. Schopf, T.R. Sergeev, V. Stratigos, A. Thomas, L. Tiodorovic, D. Vahlberg, A. Zafirovik, Z. Eurodermoscopy Working Group
Abstract: Background: Dermoscopy is a widely used technique, recommended in clinical practice guidelines worldwide for the early diagnosis of skin cancers. Intra-European disparities are reported for early detection and prognosis of skin cancers, however, no information exists about regional variation in patterns of dermoscopy use across Europe. Objective: To evaluate the regional differences in patterns of dermoscopy use and training among European dermatologists. Materials & Methods: An online survey of European-registered dermatologists regarding dermoscopy training, practice and attitudes was established. Answers from Eastern (EE) versus Western European (WE) countries were compared and their correlation with their respective countries’ gross domestic product/capita (GDPc) and total and government health expenditure/capita (THEc and GHEc) was analysed. Results: We received 4,049 responses from 14 WE countries and 3,431 from 18 EE countries. A higher proportion of WE respondents reported dermoscopy use (98% vs. 77%, p
Published: 2020

15. Risk factors, preventive behaviors and awareness of Romanian skin cancer patients: P-251

Author: Turcu, G., Popescu, I., Ghervase, L., Lupu, I., Giurcaneanu, C., and Forsea, A. M.
Published: 2013

16. Forschungsförderung am Beispiel des malignen Melanoms - Melanoma in Europe: Far from equal: AKS21/05

Author: Forsea, A.-M.
Published: 2013

17. Melanoma incidence and mortality in Europe: new estimates, persistent disparities

Author: Forsea, A. M., del Marmol, V., de Vries, E., Bailey, E. E., and Geller, A. C.
Published: 2012
Full Text: View/download PDF

18. Euromelanoma: a dermatology-led European campaign against nonmelanoma skin cancer and cutaneous melanoma. Past, present and future

Author: Stratigos, A. J., Forsea, A. M., van der Leest, R. J.T., de Vries, E., Nagore, E., Bulliard, J. L., Trakatelli, M., Paoli, J., Peris, K., Hercogova, J., Bylaite, M., Maselis, T., Correia, O., and del Marmol, V.
Published: 2012
Full Text: View/download PDF

19. Results of EAHP's 2018 Survey on Medicines Shortages

Author: Danzon, Patricia M., Kandolf Sekulovic, L., Guo, J., Agarwala, S., Hauschild, A., McArthur, G., Cinat, G., Wainstein, A., Caglevic, C., Lorigan, P., Gogas, H., Alvarez, M., Duncombe, R., Lebbe, C., Peris, K., Rutkowski, P., Stratigos, A., Forsea, A. M., De La Cruz Merino, L., Kukushkina, M., Dummer, R., Hoeller, C., Gorry, C., Bastholt, L., Herceg, D., Neyns, B., Vieira, R., Arenberger, P., Bylaite-Bucinskiene, M., Babovic, N., Banjin, M., Putnik, K., Todorovic, V., Kirov, K., Ocvirk, J., Zhukavets, A., Ymeri, A., Stojkovski, I., Garbe, C., Miljković, Nenad, Gibbons, Nicholas, Batista, Aida, Fitzpatrick, Raymond William, Underhill, Jonathan, and Horák, Petr
Subjects: medicine.medical_specialty, Metastatic melanoma, Innovative medicines, Economic shortage, 030226 pharmacology & pharmacy, Patient care, RS, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Immunooncology, Medicine, medicines shortage, 030212 general & internal medicine, General Pharmacology, Toxicology and Pharmaceutics, Hospital pharmacy, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Public health, public health, Budgetary impact, antimicrobial drugs, Access, drug procurement, Treatment, hospital pharmacy, Family medicine, Original Article, business
Abstract: Aims and objectives: \ud The aim of the 2018 EAHP Survey on Medicines Shortages was to provide a clearer picture on the issue of medicines shortages, including the impact on hospital pharmacists' time, budgets and the effect on patient care. Methods: A survey was conducted by the EAHP, collecting information from European hospital pharmacists on the shortage situation in their respective countries. The survey ran from 19 March 2018 to 11 June 2018. Keele University, UK analysed and compared the results to those of the 2014 survey. \ud \ud Results: \ud There were 1666 responses to the 2018 survey, which represented a threefold increase from the 2014 survey which received 607 responses. Ninety per cent of respondents answered 'Yes' when asked if shortages of medicines are a current problem in delivering the best care to patients, while only 7% of respondents answered 'No', and 3% 'Unsure'.Problems with shortages of antimicrobials were most commonly reported (77% of respondents reporting this as an issue in 2018 vs 57% in 2014), followed by preventative medicines (43% in 2018 vs 20% in 2014) and anaesthetics (39% in 2018 vs 27% in 2014). Fifty-nine per cent of respondents have seen care delayed as a consequence of medication shortages, with cancellations of care (31% of respondents), medication errors (25% of respondents) and suboptimal treatment for patients (25% of respondents) also being frequently reported.Sixty-three per cent of respondents reported having had to pay a higher price to procure from alternate sources most of the time or always when there was a shortage of a medicine. \ud \ud Conclusions: \ud Medicines shortages is an increasing problem across Europe and is having an adverse impact on patient care. Medicines shortages are adding to hospital pharmacists' time pressures and have an adverse budgetary impact. More timely information about impending shortages and how long they will last is seen as necessary to help manage the problem.
Published: 2019

20. Malignant melanoma with subjacent lymphomatoid reaction

Author: Forsea, D., Motirlichie, M., Forsea, A. M., Nik, H., Costache, M., and Trifu, P.
Published: 2003

21. The impact of dermoscopy on melanoma detection in the practice of dermatologists in Europe: results of a pan-European survey

Author: Forsea, A M, Tschandl, P, Zalaudek, I, Del Marmol, V, Soyer, H P, Eurodermoscopy Working Group, Argenziano, G, Geller, A C, University of Zurich, and Forsea, A M
Subjects: 2708 Dermatology, 10177 Dermatology Clinic, 610 Medicine & health, 2725 Infectious Diseases
Published: 2017

22. Factors driving the use of dermoscopy in Europe: a pan-European survey

Author: Forsea, A. M., Tschand, P., del Marmo, V., Zalaudek, I., Soyer, H. P., Arenbergerova, M., Azenha, A., Blum, A., Bowling, J. C., Braun, R. P., Bylaite-Bucinskiene, M., Cabrijan, L., Dobrev, H., Hegy, J., Helppikangas, H., Hofmann-Wellenhof, R., Karls, R., Krumkachou, U., Kukutsch, N., Mccormack, I., Mekokishvili, L., Nathansohn, N., Nielsen, K., Olah, J., Ozdemir, F., Puig, S., Rubegni, P., Rucigaj, T. P., Schopf, T. R., Sergeev, V., Stratigos, A., Thomas, L., Tiodorovic, D., Vahlberg, A., Zafirovik, Z., Geller, A. C., Argenziano, G., Forsea, A M, Tschandl, P, Del Marmol, V, Zalaudek, I, Soyer, H P, Geller, A C, Argenziano, G, Arenbergerova, M, Azenha, A, Blum, A, Bowling, Jc, Braun, Rp, Bylaite-Bucinskiene, M, Čabrijan, L, Dobrev, H, Hegyi, J, Helppikangas, H, Hofmann-Wellenhof, R, Karls, R, Krumkachou, U, Kukutsch, N, Mccormack, I, Mekokishvili, L, Nathansohn, N, Nielsen, K, Olah, J, Özdemir, F, Puig, S, Rubegni, P, Planinsek Rucigaj, T, Schopf, Tr, Sergeev, V, Stratigos, A, Thomas, L, Tiodorovic, D, Vahlberg, A, and Zafirovik, Z.
Subjects: Adult, Male, medicine.medical_specialty, Younger age, Attitude of Health Personnel, Early detection, Dermoscopy, Dermatology, Skin Diseases, Public healthcare, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Pan european, medicine, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Dermatovenerologija, Humans, business.industry, Middle Aged, Europe, Multicenter study, 030220 oncology & carcinogenesis, Family medicine, Dermatology clinic, Female, Attitude to Health, Dermatologists, dermoscopy, Dermatologist, business, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Dermatovenerology, Human
Abstract: BackgroundWhen used correctly, dermoscopy is an essential tool for helping clini-cians in the diagnosis of skin diseases and the early detection of skin cancers.Despite its proven benefits, there is a lack of data about how European dermatol-ogists use dermoscopy in everyday practice.ObjectivesTo identify the motivations, obstacles and modifiable factors influencingthe use of dermoscopy in daily dermatology practice across Europe.MethodsAll registered dermatologists in 32 European countries were invited tocomplete an online survey of 20 questions regarding demographic and practicecharacteristics, dermoscopy training and self-confidence in dermoscopic skills,patterns of dermoscopy use, reasons for not using dermoscopy and attitudesrelating to dermoscopy utility.ResultsWe collected 7480 valid answers, of which 89% reported use of der-moscopy. The main reasons for not using dermoscopy were lack of equipment(58% of nonusers) and lack of training (42%). Dermoscopy training during resi-dency was reported by 41% of dermoscopy users and by 12% of nonusers(P
Published: 2016

23. The impact of dermoscopy on melanoma detection in the practice of dermatologists in Europe: results of a pan-European survey

Author: Forsea, A. M., Tschandl, P., Zalaudek, I., del Marmol, V., Soyer, H. P., Eurodermoscopy Working Group, Argenziano, G., Geller, A. C., Arenbergerova, M., Azenha, A., Blum, A., Bowling, J. C., Braun, R. P., Bylaite-Bucinskiene, M., Čabrijan, L., Dobrev, H., Özdemir, F., Hegyi, J., Helppikangas, H., Hofmann-Wellenhof, R., Karls, R., Krumkachou, U., Kukutsch, N., Mccormack, I., Mekokishvili, L., Nathansohn, N., Nielsen, K., Olah, J., Puig, S., Rubegni, P., Planinsek Rucigaj, T., Schopf, T. R., Sergeev, V., Stratigos, A., Thomas, L., Tiodorovic, D., Vahlberg, A., Zafirovik, Z., Forsea, A. M., Tschandl, P., Zalaudek, I., Del Marmol, V., Soyer, H. P., Argenziano, G., Geller, A. C., Arenbergerova, M., Azenha, A., Blum, A., Bowling, J. C., Braun, R. P., Bylaite-Bucinskiene, M., Čabrijan, L., Dobrev, H., Özdemir, F., Hegy, i J., Helppikangas, H., Hofmann-Wellenhof, R., Karls, R., Krumkachou, U., Kukutsch, N., Mccormack, I., Mekokishvili, L., Nathansohn, N., Nielsen, K., Olah, J., Puig, S., Rubegni, P., Planinsek Rucigaj, T., Schopf, T. R., Sergeev, V., Stratigos, A., Thomas, L., Tiodorovic, D., Vahlberg, A., Zafirovik, Z., del Marmol, V., Cabrijan, L., Ozdemir, F., and Hegyi, J.
Subjects: Adult, Male, medicine.medical_specialty, Skin Neoplasms, Pattern analysis, Dermoscopy, Dermatology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Pan european, Adult, Dermatologists, Dermoscopy, Europe, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, dermoscopy, melanoma, Medicine, Humans, Skin Neoplasm, skin and connective tissue diseases, Melanoma diagnosis, Melanoma, business.industry, Middle Aged, Melanoma detection, Europe, Infectious Diseases, 030220 oncology & carcinogenesis, Dermatology clinic, Female, business, Human, Dermatologists
Abstract: Background: Dermoscopy is a widely used technique that can increase the sensitivity and specificity of melanoma detection. Information is lacking on the impact of dermoscopy use on the detection of melanoma in the real-life practice of European dermatologists. Objective: To identify factors that influence the benefit of using dermoscopy for increasing melanoma detection and lowering the number of unnecessary biopsies in the practice of European dermatologists. Methods: We conducted a survey of dermatologists registered in 32 European countries regarding the following: the demographic and practice characteristics, dermoscopy training and use, opinions on dermoscopy and the self-estimated impact of dermoscopy use on the number of melanomas detected and the number of unnecessary biopsies performed in practice. Results: Valid answers were collected for 7480 respondents, of which 6602 reported using dermoscopy. Eighty-six per cent of dermoscopy users reported that dermoscopy increased the numbers of melanomas they detected, and 70% reported that dermoscopy decreased the number of unnecessary biopsies of benign lesions they performed. The dermatologists reporting these benefits were more likely to have received dermoscopy training during residency, to use dermoscopy frequently and intensively, and to use digital dermoscopy systems and pattern analysis compared to dermatologists who did not perceive any benefit of dermoscopy for the melanoma recognition in their practice. Conclusions: Improving dermoscopy training, especially during residency and increasing access to digital dermoscopy equipment are important paths to enhance the benefit of dermoscopy for melanoma detection in the practice of European dermatologists.
Published: 2016

24. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries

Author: Kandolf Sekulovic, L. Guo, J. Agarwala, S. Hauschild, A. McArthur, G. Cinat, G. Wainstein, A. Caglevic, C. Lorigan, P. Gogas, H. Alvarez, M. Duncombe, R. Lebbe, C. Peris, K. Rutkowski, P. Stratigos, A. Forsea, A.-M. De La Cruz Merino, L. Kukushkina, M. Dummer, R. Hoeller, C. Gorry, C. Bastholt, L. Herceg, D. Neyns, B. Vieira, R. Arenberger, P. Bylaite-Bucinskiene, M. Babovic, N. Banjin, M. Putnik, K. Todorovic, V. Kirov, K. Ocvirk, J. Zhukavets, A. Ymeri, A. Stojkovski, I. Garbe, C.
Abstract: According to data from recent studies from Europe, a large percentage of patients have restricted access to innovative medicines for metastatic melanoma. Melanoma World Society and European Association of Dermato-oncology conducted a Web-based survey on access to first-line recommended treatments for metastatic melanoma by current guidelines (National Comprehensive Center Network, European Society for Medical Oncology [ESMO] and European Organization for Research and Treatment of Cancer/European Association of Dermato-oncology/European dermatology Forum) among melanoma experts from 27 European countries, USA, China, Australia, Argentina, Brazil, Chile and Mexico from September 1st, 2017 to July 1st, 2018. Data on licencing and reimbursement of medicines and the number of patient treated were correlated with the data on health expenditure per capita (HEPC), Mackenbach score of health policy performance, health technology assessment (HTA), ASCO and ESMO Magnitude of clinical benefit scale (ESMO MCBS) scores of clinical benefit and market price of medicines. Regression analysis for evaluation of correlation between the parameters was carried out using SPSS software. The estimated number of patients without access in surveyed countries was 13768. The recommended BRAFi + MEKi combination and anti-PD1 immunotherapy were fully reimbursed/covered in 19 of 34 (55.8%) and 17 of 34 (50%) countries, and combination anti-CTLA4+anti-PD1 in was fully covered in 6 of 34 (17.6%) countries. Median delay in reimbursement was 991 days, and it was in significant correlation with ESMO MCBS (p = 0.02), median market price (p = 0.001), HEPC and Mackenbach scores (p < 0.01). Price negotiations or managed entry agreements (MEAs) with national authorities were necessary for reimbursement. In conclusion, great discrepancy exists in metastatic melanoma treatment globally. Access to innovative medicines is in correlation with economic parameters as well as with healthcare system performance parameters. Patient-oriented drug development, market access and reimbursement pathways must be urgently found. © 2018 Elsevier Ltd
Published: 2018

25. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries

Author: Kandolf Sekulovic, L., primary, Guo, J., additional, Agarwala, S., additional, Hauschild, A., additional, McArthur, G., additional, Cinat, G., additional, Wainstein, A., additional, Caglevic, C., additional, Lorigan, P., additional, Gogas, H., additional, Alvarez, M., additional, Duncombe, R., additional, Lebbe, C., additional, Peris, K., additional, Rutkowski, P., additional, Stratigos, A., additional, Forsea, A.-M., additional, De La Cruz Merino, L., additional, Kukushkina, M., additional, Dummer, R., additional, Hoeller, C., additional, Gorry, C., additional, Bastholt, L., additional, Herceg, D., additional, Neyns, B., additional, Vieira, R., additional, Arenberger, P., additional, Bylaite-Bucinskiene, M., additional, Babovic, N., additional, Banjin, M., additional, Putnik, K., additional, Todorovic, V., additional, Kirov, K., additional, Ocvirk, J., additional, Zhukavets, A., additional, Ymeri, A., additional, Stojkovski, I., additional, and Garbe, C., additional
Published: 2018
Full Text: View/download PDF

26. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments

Author: Kandolf Sekulovic, L. Peris, K. Hauschild, A. Stratigos, A. Grob, J.-J. Nathan, P. Dummer, R. Forsea, A.-M. Hoeller, C. Gogas, H. Demidov, L. Lebbe, C. Blank, C. Olah, J. Bastholt, L. Herceg, D. Neyns, B. Vieira, R. Hansson, J. Rutkowski, P. Krajsova, I. Bylaite-Bucinskiene, M. Zalaudek, I. Maric-Brozic, J. Babovic, N. Banjin, M. Putnik, K. Weinlich, G. Todorovic, V. Kirov, K. Ocvirk, J. Zhukavets, A. Kukushkina, M. De La Cruz Merino, L. Ymeri, A. Risteski, M. Garbe, C.
Abstract: Background Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among different European countries. We analysed the availability of these innovative therapies in Europe and estimated the number of patients without access to first-line recommended treatment per current guidelines of professional entities such as the European Society for Medical Oncology (ESMO), the European Organisation for Research and Treatment of Cancer (EORTC), the European Association of Dermato-Oncology (EADO), and European Dermatology Forum (EDF). Materials and methods Web-based online survey was conducted in 30 European countries with questions about the treatment schedules from 1st May 2015 to 1st May 2016: number of metastatic melanoma patients, registration and reimbursement of innovative medicines (updated data, as of 1st October 2016), percentage of patients treated and availability of clinical studies and compassionate-use programmes. Results The recommended BRAF inhibitor (BRAFi) + MEK inhibitor (MEKi) combination was both registered and fully reimbursed in 9/30 (30%) countries, and in 13/30 (43%) (all from Eastern Europe) not reimbursed. First-line immunotherapy with anti-PD1 antibodies was registered and fully reimbursed in 14/30 (47%) countries, while in 13/30 (43%) (all from Eastern Europe) not reimbursed. It was estimated that in Europe 19,600 patients with metastatic melanoma are treated, and 5238 (27%) do not have access to recommended first-line therapy. Significant correlation was found between human development index (HDI, UNDP report 2015), (r = 0.662; p < 0.001), health expenditure per capita (r = 0.695; p < 0.001) and the Mackenbach score of health policy performance (r = 0.765; p < 0.001) with the percentage of patients treated with innovative medicines and a number of reimbursed medicines. Conclusions Great discrepancy exists in metastatic melanoma treatment across Europe. It is crucial to increase the awareness of national and European policymakers, oncological societies, melanoma patients' associations and pharma industry. © 2017 Elsevier Ltd
Published: 2017

27. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments

Author: Kandolf Sekulovic, L, Peris, K, Hauschild, A, Stratigos, A, Grob, J-J, Nathan, P, Dummer, R, Forsea, A-M, Hoeller, C, Gogas, H, Demidov, L, Lebbe, C, Blank, C, Olah, J, Bastholt, L, Herceg, D, Neyns, B, Vieira, R, Hansson, J, Rutkowski, P, Krajsova, I, Bylaite-Bucinskiene, M, Zalaudek, I, Maric-Brozic, J, Babovic, N, Banjin, M, Putnik, K, Weinlich, G, Todorovic, V, Kirov, K, et al, University of Zurich, and Kandolf Sekulovic, L
Subjects: 10177 Dermatology Clinic, 610 Medicine & health, 2730 Oncology, 1306 Cancer Research
Published: 2017

28. More than 5000 patients with metastatic melanoma in Europe per year do not have access to new life-saving drugs

Author: Sekulovic, L. Kandolf Peris, K. Hauschild, A. Demidov, L. V. and Nathan, P. Lebbe, C. Hoeller, C. Blank, C. Olah, J. and Gogas, H. Dummer, R. Bastholt, L. Herceg, D. and Stratigos, A. Neyns, B. Hansson, J. Rutkowski, P. and Forsea, A-M. Krajsova, I. Garbe, C.
Published: 2016

29. Evolution of melanocytic nevi under vemurafenib, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma

Author: Giurcaneanu, C., Cornelia Nitipir, Popa, L. G., Forsea, A. M., Popescu, I., and Bumbacea, R. S.
Subjects: Male, Nevus, Pigmented, Sulfonamides, Indoles, Skin Neoplasms, integumentary system, Pyridones, Biopsy, Needle, Imidazoles, Dermoscopy, Pyrimidinones, Middle Aged, Risk Assessment, Treatment Outcome, Vemurafenib, Antineoplastic Combined Chemotherapy Protocols, Oximes, Disease Progression, Humans, Neoplasm Invasiveness, skin and connective tissue diseases, neoplasms, Melanoma, Follow-Up Studies
Abstract: Treatment of advanced melanoma with selective BRAF and MEK inhibitors is associated with a series of mucocutaneous side effects, among which morphological changes in preexisting nevi and the development of new melanocytic lesions, both benign and malignant.Objective was to describe the changes observed in melanocytic nevi under vemurafenib therapy, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma.The melanocytic lesions of a 51-year-old Caucasian male patient diagnosed with stage IV melanoma were monitored both clinically and dermoscopically throughout vemurafenib, followed by combined treatment with dabrafenib and trametinib.The 65 monitored nevi presented different behaviors under vemurafenib treatment: 18 reticular nevi, 9 reticular-homogenous nevi, 3 reticular-globular nevi, and 2 globular nevi showed a diffuse decrease in pigmentation. Ten reticular nevi remained unchanged, while the rest of the nevi, independent of the dermoscopic pattern, presented a gradual increase in pigmentation. On the other hand, under dabrafenib and trametinib treatment 57 of these nevi showed gradual decrease in pigmentation and central involution, while 7 reticular nevi and 1 globular nevus remained unchanged; none of the monitored nevi increased in pigmentation nor presented new globules following this combination therapy.Systematic total body skin examination is mandatory in patients receiving BRAF inhibitors. The divergent course of melanocytic nevi during vemurafenib vs. dabrafenib and trametinib therapy remains to be elucidated by further research. KEY WORDS: melanoma; pigmented nevus; dermoscopy; vemurafenib
Published: 2015

30. More than 5000 patients with metastatic melanoma in Europe per year do not have access to new life-saving drugs

Author: Sekulovic, L. Kandolf, primary, Peris, K., additional, Hauschild, A., additional, Demidov, L.V., additional, Nathan, P., additional, Lebbe, C., additional, Hoeller, C., additional, Blank, C., additional, Olah, J., additional, Gogas, H., additional, Dummer, R., additional, Bastholt, L., additional, Herceg, D., additional, Stratigos, A., additional, Neyns, B., additional, Hansson, J., additional, Rutkowski, P., additional, Forsea, A.-M., additional, Krajsová, I., additional, and Garbe, C., additional
Published: 2016
Full Text: View/download PDF

31. Melanoma prognosis in Europe: far from equal

Author: Forsea, A. M. del Marmol, V. Stratigos, A. Geller, A. C.
Abstract: Background Comprehensive, population-based analysis of melanoma survival throughout Europe is hindered by the uneven coverage and quality of European cancer registries, and by logistical and financial shortcomings. Mortality-to-incidence ratios (MIRs) have been used as a proxy for estimating survival for multiple cancers and to model melanoma prognosis, higher MIR values reflecting poorer prognosis. Updated and improved pan-European estimates of mortality and incidence rates for melanoma have become available through the International Agency for Research of Cancer project Globocan 2008, showing marked differences among European countries. Objectives To analyse MIRs for melanoma across Europe and their relationship with national health expenditures, aiming to identify countries and regions with disproportionately poor prognosis. Methods Estimated age-standardized rates of melanoma incidence and mortality provided by Globocan 2008 were used to calculate the MIR for each European country and region. Total health expenditures per capita in European countries for 2008 were provided by the World Health Organization/Global Health Observatory. The potential correlation between MIR and total health expenditure per capita was analysed through Pearson’s correlation. Results Mortality-to-incidence ratios for melanoma ranged between 0.09 in Switzerland and 0.44 in Latvia. The regional average MIR was the highest in Central and Eastern Europe at 0.35; the lowest was in Western Europe, at 0.13. We found a strong inverse correlation between the individual nation’s total health expenditure per capita and the calculated melanoma MIR (r = -0.76, P < 0.05). Conclusions While further improvement of melanoma registration is necessary, our findings reveal sharp disparities in the prognosis of melanoma across the Continent, correlated with significant differences in health care expenditures.
Published: 2014

32. POLYGLANDULAR AUTOIMMUNE SYNDROME ASSOCIATED WITH MULTIPLE AUTOIMMUNE CONDITIONS AND ATOPIC DERMATITIS - AN UNUSUAL MANIFESTATION OF A POLYAUTOIMMUNITY PHENOTYPE.

Author: Forsea, A. M., Mihai, C., Predescu, T., Tudose, I., Margaritescu, I., and Giurcaneanu, C.
Subjects: *AUTOIMMUNE polyendocrinopathies, *AUTOIMMUNITY, *ATOPIC dermatitis treatment, *IMMUNOSUPPRESSION, *PHENOTYPES
Abstract: Introduction. The polyglandular autoimmune syndrome (PAS) type III is a rare condition defined as the coexistence of autoimmune thyroid disorder with other endocrine autoimmune diseases, including type 1 diabetes, without adrenal dysfunction. PAS may associate with other non-endocrine autoimmune diseases, overlapping with the multiple autoimmune syndromes (MAS). We present a case of PAS III/MAS type 3, including autoimmune thyroiditis, autoimmune diabetes, vitiligo, lupus erythematosus, associated with adult-onset atopic dermatitis, a combination not reported previously. Case report. A 40 years old woman, registered as nurse working in dialysis unit, previously diagnosed with vitiligo, euthyroid autoimmune thyroiditis and disseminated granuloma annulare, with personal and familial history of atopic disorders, presented in our clinic for disseminated eczematous and lichenoid cutaneous rashes. She was tested positive for antinuclear, anti-double stranded DNA and anti-histone antibodies, with inflammatory syndrome and marginal lymphopenia and she was diagnosed with systemic lupus erythematosus (SLE). Subsequently, moderate hyperglycemia, positive anti-glutamic acid decarboxylase antibodies and low C-peptide level prompted the diagnosis of autoimmune diabetes. Recurrent flexural eczematous rashes, with negative epicutaneous tests but positive specific IgE tests for common allergens fulfilled the clinical criteria for the diagnosis of atopic dermatitis. The clinical, immunological and glycemic status were controlled with low doses of oral prednisone (<0.5 mg/kg), methotrexate (10mg/week), antimalarials, metformin, emollients and photoprotection. After changing her workplace, the immunosuppressive treatment could be discontinued, and the patient maintained normal immunological and biochemical profile at 6 months follow-up. This case brings a unique perspective on the evolution, associations spectrum and the management challenges of endocrine polyautoimmunity associated with atopic diathesis. [ABSTRACT FROM AUTHOR]
Published: 2017
Full Text: View/download PDF

33. 1389O_PR - More than 5000 patients with metastatic melanoma in Europe per year do not have access to new life-saving drugs

Author: Sekulovic, L. Kandolf, Peris, K., Hauschild, A., Demidov, L.V., Nathan, P., Lebbe, C., Hoeller, C., Blank, C., Olah, J., Gogas, H., Dummer, R., Bastholt, L., Herceg, D., Stratigos, A., Neyns, B., Hansson, J., Rutkowski, P., Forsea, A.-M., Krajsová, I., and Garbe, C.
Published: 2016
Full Text: View/download PDF

34. Melanoma in Europe: North meets South, East meets West

Author: Forsea, A.-M., additional
Published: 2013
Full Text: View/download PDF

35. Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells

Author: Forsea, A-M, primary, Müller, C, additional, Riebeling, C, additional, Orfanos, C E, additional, and Geilen, C C, additional
Published: 2004
Full Text: View/download PDF

36. The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro

Author: Riebeling, C, primary, Forsea, A-M, additional, Raisova, M, additional, Orfanos, C E, additional, and Geilen, C C, additional
Published: 2002
Full Text: View/download PDF

37. The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force

Author: Garbe, C, Peris, K, Soura, E, Forsea, A M, Hauschild, A, Arenbergerova, M, Bylaite, M, Del Marmol, V, Bataille, V, Samimi, M, Gandini, S, Saiag, P, Eigentler, T K, Lallas, A, Zalaudek, I, Lebbe, C, Grob, J-J, Hoeller, C, Robert, C, Dréno, B, Arenberger, P, Kandolf-Sekulovic, L, Kaufmann, R, Malvehy, J, Puig, S, Leiter, U, Ribero, S, Papadavid, E, Quaglino, P, Bagot, M, John, S M, Richard, M-A, Trakatelli, M, Salavastru, C, Borradori, L., Marinovic, B, Enk, A, Pincelli, C, Ioannides, D, Paul, C, and Stratigos, A J
Subjects: 610 Medicine & health, 3. Good health
Abstract: BACKGROUND The incidence of skin cancers has been increasing steadily over the last decades. Although there have been significant breakthroughs in the management of skin cancers with the introduction of novel diagnostic tools and innovative therapies, skin cancer mortality, morbidity and costs heavily burden the society. OBJECTIVE Members of the European Association of Dermato-Oncology, European Academy of Dermatology and Venereology, International Dermoscopy Society, European Dermatology Forum, European Board of Dermatovenereology of the European Union of Medical Specialists and EORTC Cutaneous Lymphoma Task Force have joined this effort to emphasize the fundamental role that the specialist in Dermatology-Venereology has in the diagnosis and management of different types of skin cancer. We review the role of dermatologists in the prevention, diagnosis, treatment and follow-up of patients with melanoma, non-melanoma skin cancers and cutaneous lymphomas, and discuss approaches to optimize their involvement in effectively addressing the current needs and priorities of dermato-oncology. DISCUSSION Dermatologists play a crucial role in virtually all aspects of skin cancer management including the implementation of primary and secondary prevention, the formation of standardized pathways of care for patients, the establishment of specialized skin cancer treatment centres, the coordination of an efficient multidisciplinary team and the setting up of specific follow-up plans for patients. CONCLUSION Skin cancers represent an important health issue for modern societies. The role of dermatologists is central to improving patient care and outcomes. In view of the emerging diagnostic methods and treatments for early and advanced skin cancer, and considering the increasingly diverse skills, knowledge and expertise needed for managing this heterogeneous group of diseases, dermato-oncology should be considered as a specific subspecialty of Dermatology-Venereology.

38. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments

Author: Ketty Peris, Lev V. Demidov, Lars Bastholt, J.-J. Grob, Paul Nathan, M. Banjin, M. Kukushkina, Alexandros Stratigos, A.M. Forsea, A. Ymeri, Matilda Bylaite-Bucinskiene, Christoph Hoeller, A. Zhukavets, V. Todorovic, G. Weinlich, Claus Garbe, K. Putnik, L. Kandolf Sekulovic, Piotr Rutkowski, M. Risteski, K. Kirov, Iris Zalaudek, J. Ocvirk, Reinhard Dummer, D. Herceg, J. Maric-Brozic, Helen Gogas, Ricardo Vieira, Judit Oláh, Ivana Krajsová, N. Babovic, L. De La Cruz Merino, C. Blank, Johan Hansson, Bart Neyns, Axel Hauschild, C. Lebbé, Laboratory of Molecullar and Cellular Therapy, Laboratory for Medical and Molecular Oncology, Clinical sciences, [Sekulovic, L. Kandolf] Mil Med Acad, Fac Med, Dept Dermatol, Belgrade, Serbia, [Peris, K.] Univ Cattolica Sacro Cuore, Inst Dermatol, Rome, Italy, [Hauschild, A.] Univ Hosp Schleswig Holstein UKSH, Dept Dermatol, Campus Kiel, Kiel, Germany, [Stratigos, A.] Univ Athens, Athens, Greece, [Gogas, H.] Univ Athens, Athens, Greece, [Grob, J. -J.] Hop la Timone, Serv Dermatol & Cancerol Cutanee, Marseille, France, [Nathan, P.] Mt Vernon Canc Ctr, Northwood, Middx, England, [Dummer, R.] Univ Hosp, Univ Spital Zurich, Skin Canc Ctr, Zurich, Switzerland, [Forsea, A. -M.] Carol Davila Univ Med & Pharm, Elias Univ Hosp Bucharest, Bucharest, Romania, [Hoeller, C.] Med Univ Vienna, Dept Dermatol, Vienna, Austria, [Demidov, L.] NN Blokhin Russian Canc Res Ctr, Moscow, Russia, [Lebbe, C.] Hosp St Louis, APHP, Paris, France, [Blank, C.] Netherland Canc Inst, Amsterdam, Netherlands, [Olah, J.] Univ Szeged, Dept Dermatol & Allergol, Szeged, Hungary, [Bastholt, L.] Odense Univ Hosp, Dept Oncol, Odense, Denmark, [Herceg, D.] Univ Hosp Zagreb, Dept Oncol, Zagreb, Croatia, [Neyns, B.] VUB, Univ Ziekenhuis Brussel, Dept Med Oncol, Brussels, Belgium, [Vieira, R.] Univ Coimbra, Fac Med, Dept Dermatol, Coimbra, Portugal, [Hansson, J.] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden, [Hansson, J.] Karolinska Univ Hosp Solna, Stockholm, Sweden, [Rutkowski, P.] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland, [Rutkowski, P.] Inst Oncol, Warsaw, Poland, [Krajsova, I.] Gen Teaching Hosp, Prague, Czech Republic, [Bylaite-Bucinskiene, M.] Vilnius Univ, Dept Dermatol, Vilnius, Lithuania, [Zalaudek, I.] Med Univ Graz, Div Dermatol & Venerol, Graz, Austria, [Maric-Brozic, J.] Univ Hosp Ctr Sestre Milosrdnice, Zagreb, Croatia, [Babovic, N.] Inst Oncol & Radiol Serbia, Belgrade, Serbia, [Banjin, M.] Univ Hosp Sarajevo, Dept Oncol, Sarajevo, Bosnia & Herceg, [Putnik, K.] North Estonia Med Ctr, Tallinn, Estonia, [Weinlich, G.] Med Univ Innsbruck, Dept Dermatol & Venerol & Allergy, Innsbruck, Austria, [Todorovic, V.] Clin Oncol & Radiotherapy, Podgorica, Montenegro, [Kirov, K.] Natl Canc Ctr, Clin Oncodermatol, Sofia, Bulgaria, [Ocvirk, J.] Inst Oncol Ljubljana, Ljubljana, Slovenia, [Zhukavets, A.] NN Alexandrov Natl Canc Ctr Belarus NCCB, Minsk, BELARUS, [Kukushkina, M.] Natl Canc Inst, Kiev, Ukraine, [De La Cruz Merino, L.] Hosp Univ Virgen Macarena, Dept Clin Oncol, Seville, Spain, [Ymeri, A.] Univ Hosp Mother Theresa, Tirana, Albania, [Risteski, M.] Univ Clin Radiotherapy & Oncol, Skopje, Macedonia, [Garbe, C.] Eberhard Karls Univ Tubingen, Dept Dermatol, Ctr Dermatooncol, Tubingen, Germany, Kandolf Sekulovic, L., Peris, K., Hauschild, A., Stratigos, A., Grob, J. -J., Nathan, P., Dummer, R., Forsea, A. -M., Hoeller, C., Gogas, H., Demidov, L., Lebbe, C., Blank, C., Olah, J., Bastholt, L., Herceg, D., Neyns, B., Vieira, R., Hansson, J., Rutkowski, P., Krajsova, I., Bylaite-Bucinskiene, M., Zalaudek, I., Maric-Brozic, J., Babovic, N., Banjin, M., Putnik, K., Weinlich, G., Todorovic, V., Kirov, K., Ocvirk, J., Zhukavets, A., Kukushkina, M., De La Cruz Merino, L., Ymeri, A., Risteski, M., and Garbe, C.
Subjects: Human development index, Male, Cancer Research, Skin Neoplasms, Survival, medicine.medical_treatment, Access, Health expenditure per capita, Immunooncology, Innovative medicines, Metastatic melanoma, Targeted therapy, Treatment, Acrylonitrile, Aniline Compounds, Antibodies, Monoclonal, Humanized, Europe, Female, Health Services Accessibility, Healthcare Disparities, Humans, Immunotherapy, Melanoma, Programmed Cell Death 1 Receptor, Proto-Oncogene Proteins B-raf, Reimbursement Mechanisms, Therapies, Investigational, Oncology, Investigational, Reimbursement Mechanism, Melanoma/economics, Disparities, Immuno oncology, Medicines, 0302 clinical medicine, Diagnosis, Health care, Monoclonal, 030212 general & internal medicine, Healthcare Disparities/economics, Acce, Acrylonitrile/analogs & derivatives, Humanized, Proto-Oncogene Proteins B-raf/antagonists & inhibitors, Reimbursement, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Aniline Compound, Healthcare Disparitie, Health Services Accessibility/economics, 030220 oncology & carcinogenesis, Targeted therapy Health, Innovative medicine, Health-care, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Treatment Immunooncology, Human, medicine.medical_specialty, Reimbursement Mechanisms/statistics & numerical data, Union, Antibodies, Europe/epidemiology, Malignant-melanoma, 03 medical and health sciences, Pharmacotherapy, Internal medicine, medicine, Skin Neoplasm, Human Development Index, Mortality, Therapies, Investigational/economics, Skin Neoplasms/economics, Health policy, business.industry, Cancer, medicine.disease, access, innovative medicines, metastatic melanoma, treatment, immunooncologytargeted therapyhealth expenditure per capita, human development index, Surgery, Immunotherapy/economics, Therapies, Aniline Compounds/economics, Skin cancer, business, Cancer incidence, Antibodies, Monoclonal, Humanized/economics
Abstract: Background. Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among different European countries. We analysed the availability of these innovative therapies in Europeand estimated the number of patients without access to first-line recommended treatment per current guidelines of professional entities such as the European Society for Medical Oncology (ESMO), the European Organisation for Research and Treatment of Cancer (EORTC), the European Association of Dermato-Oncology (EADO), and European Dermatology Forum (EDF). Materials and methods Web-based online survey was conducted in 30 European countries with questions about the treatment schedules from 1st May 2015 to 1st May 2016: number of metastatic melanoma patients, registration and reimbursement of innovative medicines (updated data, as of 1st October 2016), percentage of patients treated and availability of clinical studies and compassionate-use programmes. Results The recommended BRAF inhibitor (BRAFi)+MEK inhibitor (MEKi) combination was both registered and fully reimbursed in 9/30 (30%) countries, and in 13/30 (43%) (all from Eastern Europe) not reimbursed. First-line immunotherapy with anti-PD1 antibodies was registered and fully reimbursed in 14/30 (47%) countries, while in 13/30 (43%) (all from Eastern Europe) not reimbursed. It was estimated that in Europe 19,600 patients with metastatic melanoma are treated, and 5238 (27%) do not have access to recommended first-line therapy. Significant correlation was found between human development index (HDI, UNDP report 2015), (r=0.662; p Previous article in issue
Published: 2017

39. Inequalities in the patterns of dermoscopy use and training across Europe: conclusions of the Eurodermoscopy pan-European survey

Author: Ana-Maria, Forsea, Philipp, Tschandl, Iris, Zalaudek, Veronique, Del Marmol, H Peter, Soyer, Monika, Arenbergerova, Angelo, Azenha, Andreas, Blum, Jonathan C., Bowling, Ralph P., Braun, Matilda, Bylaite-Bucinskiene, Leo, Cabrijan, Hristo, Dobrev, Hana, Helppikangas, Raimonds, Karls, Uladzimir, Krumkachou, Nicole, Kukutsch, Iona, Mccormack, Lali, Mekokishvili, Nir, Nathansohn, Kari, Nielsen, Judit, Olah, Fezal, Özdemir, Susana, Puig, Pietro, Rubegni, Tanja, Planinsek Rucigaj, Thomas R., Schopf, Vasily, Sergeev, Alexander, Stratigos, Luc, Thomas, Danica, Tiodorovic, Ave, Vahlberg, Zorica, Zafirovik, Giuseppe, Argenziano, Alan C, Geller, University of Zurich, Forsea, A. -M., Tschandl, P., Zalaudek, I., Del Marmol, V., Soyer, H. P., Argenziano, G., and Geller, A. C.
Subjects: Adult, Male, Skin Neoplasms, Inequality, media_common.quotation_subject, Psychological intervention, Western Europe, Early detection, 610 Medicine & health, dermoscopy, training, skin cancer, Western Europe, Eastern Europe, disparities, Eastern Europe, Dermatology, 2708 Dermatology, Pan european, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Dermatovenerologija, Per capita, Humans, Medicine, Practice Patterns, Physicians', disparities, media_common, training, skin cancer, business.industry, 10177 Dermatology Clinic, Middle Aged, Prognosis, medicine.disease, Europe, Clinical Practice, Early Diagnosis, Health Care Surveys, Female, Clinical Competence, dermoscopy, Skin cancer, business, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Dermatovenerology, Procedures and Techniques Utilization, Regional differences, Dermatologists, disparitie, Demography
Abstract: BACKGROUND: Dermoscopy is a widely used technique, recommended in clinical practice guidelines worldwide for the early diagnosis of skin cancers. Intra-European disparities are reported for early detection and prognosis of skin cancers, however, no information exists about regional variation in patterns of dermoscopy use across Europe. OBJECTIVE: To evaluate the regional differences in patterns of dermoscopy use and training among European dermatologists. MATERIALS & METHODS: An online survey of European-registered dermatologists regarding dermoscopy training, practice and attitudes was established. Answers from Eastern (EE) versus Western European (WE) countries were compared and their correlation with their respective countries' gross domestic product/capita (GDPc) and total and government health expenditure/capita (THEc and GHEc) was analysed. RESULTS: We received 4,049 responses from 14 WE countries and 3,431 from 18 EE countries. A higher proportion of WE respondents reported dermoscopy use (98% vs. 77%, p
Published: 2020

40. The daily use of dermoscopy in the Netherlands

Author: Judith Zoutendijk, Denny Siem, Giuseppe Argenziano, Ana-Maria Forsea, Alan Geller, Veronique Del Marmol, Iris Zalaudek, Peter Soyer, Nicole Kukutsch, Zoutendijk, J., Siem, D., Argenziano, G., Forsea, A. -M., Geller, A., Del Marmol, V., Zalaudek, I., Soyer, P., and Kukutsch, N.
Subjects: SDG 3 - Good Health and Well-being, pigment, melanoma, Dermatology, dermoscopy, inflammatory disease
Abstract: Background: Dermoscopy is a well-established tool for the diagnosis of skin diseases and skin cancer. Data on the use of dermoscopy by Dutch dermatologists is lacking. Objectives: To identify factors influencing the use of dermoscopy in daily dermatology practice and compare the results with those from other European countries. Materials & Methods: As a part of a pan-European study, all registered dermatologists in the Netherlands were asked to complete an online survey regarding questions about training and attitude towards dermoscopy. Results: Valid answers were collected from 213 respondents (out of 475 registered dermatologists), of whom 99% reported using dermoscopy. Of those, 41% reported dermoscopy training during residency. A high level of dermoscopy use for different types of skin diseases was reported by 28.9%. Users considered dermoscopy useful for pigmented lesions, especially for the early diagnosis of melanoma, but less advantageous for inflammatory diagnoses. Seventy-three percent reported that dermoscopy increased the number of melanomas detected compared to naked eye diagnosis, and two-thirds reported a decrease in unnecessary biopsies of benign lesions. Almost one third reported that on at least one occasion, a lesion that appeared benign on dermoscopy proved to be a melanoma after excision. Conclusion: This study reveals that nearly all Dutch dermatologists use dermoscopy, particularly for melanocytic lesions, but less so for inflammatory diagnoses. Most believe that they detected more melanomas as a result of using dermoscopy compared to the naked eye. A high level of dermoscopy use was significantly associated with seeing more skin cancer patients each month compared to infrequent use.
Published: 2022

41. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention

Author: Stratigos, Alexander J, Garbe, Claus, Dessinioti, Clio, Lebbe, Celeste, Bataille, Veronique, Bastholt, Lars, Dreno, Brigitte, Fargnoli, Maria Concetta, Forsea, Ana Maria, Frenard, Cecille, Harwood, Catherine Α, Hauschild, Axel, Hoeller, Christoph, Kandolf-Sekulovic, Lidija, Kaufmann, R, Kelleners-Smeets, Nicole Wj, Malvehy, Josep, Del Marmol, Veronique, Middleton, Mark R, Moreno-Ramirez, David, Pellecani, Giovanni, Peris, Ketty, Saiag, Philippe, van den Beuken-van Everdingen, Marieke H J, Vieira, Ricardo, Zalaudek, Iris, Eggermont, Alexander M M, Grob, Jean-Jacques, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC), National and Kapodistrian University of Athens (NKUA), Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), North & East Hertfordshire NHS Trust [Northwood, UK], Odense University Hospital (OUH), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), University of L'Aquila [Italy] (UNIVAQ), University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Queen Mary University of London (QMUL), Kiel University, Medizinische Universität Wien = Medical University of Vienna, Military Medical Academy [Belgrade, Serbia] (2MA), Frankfurt University Hospital, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III [Madrid] (ISC), Université libre de Bruxelles (ULB), Hôpital Erasme [Bruxelles], University of Oxford, Hospital Universitario Virgen Macarena [Sevilla, Spain] (HUVM), University - Hospital of Modena and Reggio Emilia [Modena, Italy], Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Istituto Neurologico Mediterraneo (NEUROMED I.R.C.C.S.), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA)-University of Naples Federico II = Università degli studi di Napoli Federico II, Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Hôpital Ambroise Paré [AP-HP], University Veterinary Hospital [Coimbra, Portugal], Università degli studi di Trieste = University of Trieste, Princess Máxima Center for Pediatric Oncology, Assistance Publique - Hôpitaux de Marseille (APHM), Aix Marseille Université (AMU), Novartis Les Laboratories Pierre Fabre Sanofi Bristol-Myers Squibb, BMS Pfizer Amgen Roche LEO Pharma Research Foundation Cilag Merck Meso Scale Diagnostics, MSD Genentech, The guidelines were supported by grants from the EADO for the guideline meetings. The authors did this work on a voluntary basis and did not receive any honorarium or reimbursements. Guidelines development group members stated their conflicts of interest in the relevant section., Dr. Stratigos reports personal fees and/or research support from Novartis , Roche , BMS , Abbvie , Sanofi , Regeneron , Genesis Pharma , outside the submitted work. Dr. Garbe reports personal fees from Amgen , personal fees from MSD , grants and personal fees from Novartis , grants and personal fees from NeraCare, grants and personal fees from BMS , personal fees from Pierre Fabre , personal fees from Philogen, grants and personal fees from Roche , grants and personal fees from Sanofi , outside the submitted work. Dr. Dessinioti has nothing to disclose. Dr. Lebbe reports grants and personal fees from Bristol-Myers Squibb , personal fees from MSD , personal fees from Novartis , personal fees from Amgen , grants and personal fees from Roche , personal fees from Avantis Medical Systems, personal fees from Pierre Fabre , personal fees from Pfizer , personal fees from Incyte, outside the submitted work. Dr. Bataille reports personal fees from Novartis , personal fees from Merck MSD , outside the submitted work. Dr. Bastholt reports personal fees for advisory board activity: BMS , Roche , Novartis , Pierre-Fabre, Astra Zeneca, InCyte, MSD / Merck , Bayer . Dr. Dréno reports grants and personal fees from BMS , personal fees from MSD , grants and personal fees from Roche , grants and personal fees from Fabre, grants and personal fees from Sanofi , outside the submitted work. Dr. Fargnoli reports grants and personal fees from Almirall, grants and personal fees from Leo Pharma, personal fees from Janssen, grants and personal fees from Novartis , personal fees from Lilly , grants and personal fees from Sanofi , personal fees from UCB , grants and personal fees from Abbvie , personal fees from Celgene , personal fees from Pierre Fabre , grants and personal fees from Galderma , personal fees from Mylan, personal fees from Medac Pharma, personal fees from Roche , personal fees from Sun Pharma , outside the submitted work. Dr. Forsea reports scientific consultant/speaker fee from Novartis , Leo Pharma, Solartium, Pierre-Fabre, outside the submitted work. Dr. Frenard has nothing to disclose. Dr. Harwood reports institutional research grants and honoraria from Sanofi , Novartis , Merck , Pfizer , Galderma , MEDA, Almirall, Pellepharm, Leo Pharma, CERIES. Dr. Hauschild reports honoraria and/or research grants from: Almirall, BMS , Roche , Novartis , Pierre-Fabre, Sunpharma, MerckSerono, SanofiAventis, Regeneron , MSD / Merck , Philogen, OncoSec outside the submitted work. Dr. Hoeller reports grants and personal fees from Amgen , personal fees from BMS , personal fees from MSD , personal fees from Novartis , personal fees from Pierre Fabre , personal fees from Roche , personal fees from Sanofi , personal fees from Incyte, outside the submitted work. Dr. Kandolf-Sekulovic reports speakers’ honoraria for Roche, Novartis, MSD, BMS, Janssen outside the submitted work. Dr. Kaufmann reports institutional research grants (clinical trials) from: AbbVie , Amgen , Biontech, BMS , Celgene , Galderma , Janssen, Leo, Lilly , Merck , MSD , Novartis , Pierre Fabre , Pfizer , Regeneron , Roche , Wyeth . Advisory Board and Honoraria from Merz, Roche, Novartis. Dr. Kelleners-Smeets reports grants from Netherlands Organization for Health Research and Development, other from Janssen-Cilag, other from AbbVie , other from Galderma , outside the submitted work. Dr. Malvehy reports research grants from Almirall, ISDIN, Leo Pharma, Galderma , GSK , Cantabria, participation in advisory board meetings for Almirall, Sunpharma, BMS , Roche , Novartis , Pierre-Fabre. Dr. del Marmol reports personal fees from MSD , from BMS , personal fees from Sanofi , grants and personal fees from ABVIE, grants from Jansen, outside the submitted work. Dr. Middleton reports personal fees and/or grants from Amgen , Roche , Astrazeneca, GSK , Novartis , Immunocore, BMS , Eisai and Merck . Institutional funding from Millennium, Vertex, Pfizer , Regeneron , TCBiopharma, BiolineRx, Replimune, outside the submitted work. Dr. Moreno-Ramírez has nothing to disclose. Dr. Pellecani reports grants from university of modena and reggio emilia, during the conduct of the study, grants from novartis, grants and personal fees from almirall, grants from leo pharma, from null, outside the submitted work. Dr. Peris reports honoraria for advisory board and grants from AbbVie , Almirall, Biogen Celgene , Lilly , Galderma , Leo Pharma, Novartis , Roche , Sanofi , Sun Pharma , Sandoz outside the submitted work. Dr. Saiag reports honoraria for advisory board and grants from Amgen , Bristol-Myers Squibb , MSD , Merck-Serono, Novartis , Pfizer , Roche- Genentech , Pierre Fabre , and Sanofi , outside the submitted work. Dr. van den Beuken-van Everdingen has nothing to disclose. Dr. Vieira has nothing to disclose. Dr. Zalaudek reports honoraria and advisory board and grants from Sanofi , Sun Pharma , Novartis , Galderma , Roche , Celgene , Almirall, Leofarma, Mylan, Difa Cooper, Cieffe Labs, La Roche Posay, Pierre Fabre . Dr. Eggermont reports over the last 5 years personal fees as a consultant advisor for Biocad, BioInvent, Bristol Myers Squibb ( BMS ), CatalYm, Ellipses, Glaxo Smith Kline ( GSK ), HalioDX, Incyte, IO Biotech, ISA Pharmaceuticals, Merck Sharpe & Dohme ( MSD ), Novartis , Pfizer , Polynoma, Regeneron , Sanofi , Sellas, SkylineDx. Dr. Grob reports personal fees for advisory board and as speaker from Amgen , Roche , GSK , Novartis , BMS , Pierre fabre, Merck , Sanofi , Merck , Pfizer outside the submitted work., European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC), HAL UVSQ, Équipe, Dermatologie, MUMC+: MA Dermatologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, RS: MHeNs - R3 - Neuroscience, MUMC+: TPZ Palliatieve Zorg (9), Stratigos, A. J., Garbe, C., Dessinioti, C., Lebbe, C., Bataille, V., Bastholt, L., Dreno, B., Fargnoli, M. C., Forsea, A. M., Frenard, C., Harwood, C. Alpha., Hauschild, A., Hoeller, C., Kandolf-Sekulovic, L., Kaufmann, R., Kelleners-Smeets, N. W., Malvehy, J., del Marmol, V., Middleton, M. R., Moreno-Ramirez, D., Pellecani, G., Peris, K., Saiag, P., van den Beuken-van Everdingen, M. H. J., Vieira, R., Zalaudek, I., Eggermont, A. M. M., Grob, J. -J., Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)
Subjects: 0301 basic medicine, Cancer Research, Skin Neoplasms, Staging, Medical Oncology, Palpation, Imaging, Low-risk, 0302 clinical medicine, Protective Clothing, Metastatic cSCC, Positron Emission Tomography Computed Tomography, Diagnosis, Epidemiology, Societies, Medical, AMERICAN JOINT COMMITTEE, Skin, Ultrasonography, Invasive cutaneous squamous cell carcinoma, medicine.diagnostic_test, NONSTEROIDAL ANTIINFLAMMATORY DRUGS, High-risk common primary cSCC, RANDOMIZED CONTROLLED-TRIAL, Prognosis, Magnetic Resonance Imaging, 3. Good health, LYMPH-NODE BIOPSY, Oncology, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, Sunlight, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Diagnosi, medicine.medical_specialty, Consensus, Prognosi, Sentinel lymph node, Locally advanced Cscc, Prevention, Dermatology, Humans, Lymph Nodes, Neoplasm Staging, Patient Education as Topic, Risk Assessment, Sunscreening Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, Physical examination, PERINEURAL INVASION, 03 medical and health sciences, BASAL-CELL, [SDV.CAN] Life Sciences [q-bio]/Cancer, Medical, Biopsy, medicine, CANCER PREVENTION, ORGAN TRANSPLANT RECIPIENTS, business.industry, Carcinoma, Cancer, Magnetic resonance imaging, Guideline, medicine.disease, Cancérologie, HIGH-RISK, 030104 developmental biology, Squamous Cell, SUN PROTECTION, Societies, business
Abstract: Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in the white populations, accounting for 20% of all cutaneous malignancies. Factors implicated in cSCC etiopathogenesis include ultraviolet radiation exposure and chronic photoaging, age, male sex, immunosuppression, smoking and genetic factors. A collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation of Research and Treatment of Cancer (EORTC) was formed to update recommendations on cSCC classification, diagnosis, risk stratification, staging and prevention, based on current literature, staging systems and expert consensus. Common cSCCs are typically indolent tumors, and most have a good prognosis with 5-year cure rates of greater than 90%, and a low rate of metastases (, SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2020

42. The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV–UEMS and EORTC Cutaneous Lymphoma Task Force

Author: Ulrike Leiter, Thomas Eigentler, Veronique Bataille, Alexandros Stratigos, Carmen Salavastru, Martine Bagot, Joseph Malvehy, A.M. Forsea, Marie Aleth Richard, Ketty Peris, Roland Kaufmann, Branka Marinović, Claus Garbe, Efthymia Soura, S.M. John, Axel Hauschild, Iris Zalaudek, J.-J. Grob, Monika Arenbergerova, Carlo Pincelli, Sara Gandini, Alexander Enk, Christoph Hoeller, V. Del Marmol, Brigitte Dréno, Pietro Quaglino, E. Papadavid, Luca Borradori, Aimilios Lallas, Lidija Kandolf-Sekulović, Simone Ribero, Philippe Saiag, Carle Paul, S. Puig, P. Arenberger, Céleste Lebbé, Myrto Trakatelli, Mahtab Samimi, M. Bylaite, C. Robert, D. Ioannides, CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut Gustave Roussy (IGR), Oncologie dermatologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Centre hospitalier universitaire de Nantes (CHU Nantes), Service de dermatologie (CHU de Toulouse), CHU Toulouse [Toulouse], We acknowledge the members of the Skin Cancer Unit and the Dermatology Department of the Hospital Clinic of Barcelona. We acknowledge the support by Maarten Vermeer, Antonio Cozzio, Rudolf Stadler, Pablo Ortiz-Romero, Julia Scarisbrick and Robert Knobler. Open access funding enabled and organized by Projekt DEAL., Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), National and Kapodistrian University of Athens (NKUA), University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Christian-Albrechts University of Kiel, Charles University [Prague] (CU), Vilnius University [Vilnius], Université libre de Bruxelles (ULB), King‘s College London, European Institute of Oncology [Milan] (ESMO), Hôpital Ambroise Paré [AP-HP], Universitätsklinikum Tübingen - University Hospital of Tübingen, Aristotle University of Thessaloniki, Università degli studi di Trieste = University of Trieste, Aix Marseille Université (AMU), Medizinische Universität Wien = Medical University of Vienna, Université Paris-Saclay, Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), University of Defense, Frankfurt University Hospital, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Università degli studi di Torino = University of Turin (UNITO), University of Osnabrueck, Colentina University Hospital, Bern University Hospital [Berne] (Inselspital), Zagreb School of Medicine [Zagreb, Croatia] (Dubrava University Hospital), University of Zagreb, Heidelberg University Hospital [Heidelberg], University of Modena and Reggio Emilia, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Garbe, C., Peris, K., Soura, E., Forsea, A. M., Hauschild, A., Arenbergerova, M., Bylaite, M., del Marmol, V., Bataille, V., Samimi, M., Gandini, S., Saiag, P., Eigentler, T. K., Lallas, A., Zalaudek, I., Lebbe, C., Grob, J. -J., Hoeller, C., Robert, C., Dreno, B., Arenberger, P., Kandolf-Sekulovic, L., Kaufmann, R., Malvehy, J., Puig, S., Leiter, U., Ribero, S., Papadavid, E., Quaglino, P., Bagot, M., John, S. M., Richard, M. -A., Trakatelli, M., Salavastru, C., Borradori, L., Marinovic, B., Enk, A., Pincelli, C., Ioannides, D., Paul, C., Stratigos, A. J., and HAL UVSQ, Équipe
Subjects: medicine.medical_specialty, Venereology, Skin Neoplasms, Dermatologists, Humans, Dermatology, Melanoma, Skin Diseases, [SDV]Life Sciences [q-bio], MEDLINE, 610 Medicine & health, Subspecialty, Cutaneous lymphoma, Self-Examination, Familial Atypical Multiple Mole Melanoma Syndrome, Task (project management), 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, medicine, media_common.cataloged_instance, dermato-oncology, Skin Neoplasm, European union, Intensive care medicine, media_common, business.industry, dermatooncology, role of dermatologists, cutaneous lymphoma, skin carcinoma, medicine.disease, 3. Good health, [SDV] Life Sciences [q-bio], Infectious Diseases, 030220 oncology & carcinogenesis, Position paper, Skin cancer, business, Settore MED/35 - MALATTIE CUTANEE E VENEREE
Abstract: International audience; Background: The incidence of skin cancers has been increasing steadily over the last decades. Although there have been significant breakthroughs in the management of skin cancers with the introduction of novel diagnostic tools and innovative therapies, skin cancer mortality, morbidity and costs heavily burden the society. Objective: Members of the European Association of Dermato-Oncology, European Academy of Dermatology and Venereology, International Dermoscopy Society, European Dermatology Forum, European Board of Dermatovenereology of the European Union of Medical Specialists and EORTC Cutaneous Lymphoma Task Force have joined this effort to emphasize the fundamental role that the specialist in Dermatology–Venereology has in the diagnosis and management of different types of skin cancer. We review the role of dermatologists in the prevention, diagnosis, treatment and follow-up of patients with melanoma, non-melanoma skin cancers and cutaneous lymphomas, and discuss approaches to optimize their involvement in effectively addressing the current needs and priorities of dermato-oncology. Discussion: Dermatologists play a crucial role in virtually all aspects of skin cancer management including the implementation of primary and secondary prevention, the formation of standardized pathways of care for patients, the establishment of specialized skin cancer treatment centres, the coordination of an efficient multidisciplinary team and the setting up of specific follow-up plans for patients. Conclusion: Skin cancers represent an important health issue for modern societies. The role of dermatologists is central to improving patient care and outcomes. In view of the emerging diagnostic methods and treatments for early and advanced skin cancer, and considering the increasingly diverse skills, knowledge and expertise needed for managing this heterogeneous group of diseases, dermato-oncology should be considered as a specific subspecialty of Dermatology–Venereology.
Published: 2020

43. GENDER-RELATED DIFFERENCES IN THE PRACTICES AND ATTITUDES OF EARLY DETECTION IN RUMANIAN SKIN CANCER PATIENTS.

Author: Popescu, I., Turcu, G., Ghervase, L., Forsea, A. M., and Giurcaneanu, C.
Subjects: *GENDER differences (Psychology), *SKIN cancer patients, *CANCER prognosis, *HEALTH surveys, *QUESTIONNAIRES
Abstract: Context. Advanced skin cancers have high mortality and morbidity, and early detection is crucial for prognosis. Information regarding the patterns of skin self-examination and tumor early detection in the Central and Eastern Europe is scarce. Objective. Analyze the gender differences in the practices and attitudes related to skin cancer early detection of skin cancer patients in Romania. Methods. Prospective questionnaire- based survey of patients with confirmed diagnosis of skin cancer, registered in a university reference center for dermatooncology between 2011-2012. Results. 122 skin cancer patients completed the survey (response rate 72%). Female skin cancer patients reported lower level of education and likelihood to receive a medical full skin examination. Women were more likely to check their own skin and to detect suspicious lesions on themselves and their partners than men. They delayed longer the presentation to a physician after noticing a suspicious lesion (11.4 months vs. 6.4 months median). 90.76% of all skin cancer patients were not warned by any doctor about their skin cancer risk; 30% of them never check their skin. Conclusions. Women tend to be more concerned about their skin than men, but receive less medical attention and delay longer the diagnosis. Our study also signaled an urgent need of improving the patients and physicians education for skin cancer early detection in Romania. [ABSTRACT FROM AUTHOR]
Published: 2013
Full Text: View/download PDF

44. Position statement of the EADV Melanoma Task Force on recommendations for the management of cutaneous melanoma patients during COVID-19.

Author: Arenbergerova M, Lallas A, Nagore E, Rudnicka L, Forsea AM, Pasek M, Meier F, Peris K, Olah J, and Posch C
Subjects: Humans, SARS-CoV-2, COVID-19, Melanoma therapy, Skin Neoplasms therapy
Published: 2021
Full Text: View/download PDF

45. The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force.

Author: Garbe C, Peris K, Soura E, Forsea AM, Hauschild A, Arenbergerova M, Bylaite M, Del Marmol V, Bataille V, Samimi M, Gandini S, Saiag P, Eigentler TK, Lallas A, Zalaudek I, Lebbe C, Grob JJ, Hoeller C, Robert C, Dréno B, Arenberger P, Kandolf-Sekulovic L, Kaufmann R, Malvehy J, Puig S, Leiter U, Ribero S, Papadavid E, Quaglino P, Bagot M, John SM, Richard MA, Trakatelli M, Salavastru C, Borradori L, Marinovic B, Enk A, Pincelli C, Ioannides D, Paul C, and Stratigos AJ
Subjects: Dermatologists, Humans, Dermatology, Melanoma, Skin Diseases, Skin Neoplasms diagnosis, Skin Neoplasms therapy, Venereology
Abstract: Background: The incidence of skin cancers has been increasing steadily over the last decades. Although there have been significant breakthroughs in the management of skin cancers with the introduction of novel diagnostic tools and innovative therapies, skin cancer mortality, morbidity and costs heavily burden the society., Objective: Members of the European Association of Dermato-Oncology, European Academy of Dermatology and Venereology, International Dermoscopy Society, European Dermatology Forum, European Board of Dermatovenereology of the European Union of Medical Specialists and EORTC Cutaneous Lymphoma Task Force have joined this effort to emphasize the fundamental role that the specialist in Dermatology-Venereology has in the diagnosis and management of different types of skin cancer. We review the role of dermatologists in the prevention, diagnosis, treatment and follow-up of patients with melanoma, non-melanoma skin cancers and cutaneous lymphomas, and discuss approaches to optimize their involvement in effectively addressing the current needs and priorities of dermato-oncology., Discussion: Dermatologists play a crucial role in virtually all aspects of skin cancer management including the implementation of primary and secondary prevention, the formation of standardized pathways of care for patients, the establishment of specialized skin cancer treatment centres, the coordination of an efficient multidisciplinary team and the setting up of specific follow-up plans for patients., Conclusion: Skin cancers represent an important health issue for modern societies. The role of dermatologists is central to improving patient care and outcomes. In view of the emerging diagnostic methods and treatments for early and advanced skin cancer, and considering the increasingly diverse skills, knowledge and expertise needed for managing this heterogeneous group of diseases, dermato-oncology should be considered as a specific subspecialty of Dermatology-Venereology., (© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.)
Published: 2020
Full Text: View/download PDF

46. Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer.

Author: Chernyshov PV, Lallas A, Tomas-Aragones L, Arenbergerova M, Samimi M, Manolache L, Svensson A, Marron SE, Sampogna F, Spillekom-vanKoulil S, Bewley A, Forsea AM, Jemec GB, Szepietowski JC, Augustin M, and Finlay AY
Subjects: Case-Control Studies, Europe, Humans, Treatment Outcome, Melanoma physiopathology, Quality of Life, Skin Neoplasms physiopathology
Abstract: The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer (NMSC) present a review of the literature and position statement on health-related (HR) QoL assessment in skin cancer patients. A literature search was carried out to identify publications since 1980 that included information about the impact of SC on QoL. Generic, dermatology-specific, cancer-specific, SC-specific, facial SC-specific, NMSC-specific, basal cell carcinoma-specific and melanoma-specific QoL questionnaires have been used to assess HRQoL in SC patients. HRQoL was assessed in the context of creation and validation of the HRQoL instruments, clinical trials, comparison of QoL in SC and other cancers, other diseases or controls, HRQoL assessment after treatment, comorbidities, behaviour modification, predictors of QoL and survival, supportive care needs, coping strategies and fear of cancer recurrence. The most widely used instruments for HRQoL assessment in SC patients are the European Organisation for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ-C30), the Functional Assessment of Cancer Therapy-Melanoma (FACT-M), Skin Cancer Index (SCI), Short Form 36 Item Health Survey (SF-36) and the Dermatology Life Quality Index (DLQI). The TFs recommend the use of the cancer-specific EORTC QLQ-C30, especially in late stages of disease, and the melanoma-specific FACT-M and SC-specific SCI questionnaires. These instruments have been well validated and used in several studies. Other HRQoL instruments, also with good basic validation, are not currently recommended because the experience of their use is too limited. Dermatology-specific HRQoL instruments can be used to assess the impact of skin-related problems in SC. The TFs encourage further studies to validate HRQoL instruments for use in different stages of SC, in order to allow more detailed practical recommendations on HRQoL assessment in SC., (© 2019 European Academy of Dermatology and Venereology.)
Published: 2019
Full Text: View/download PDF

47. Who, why, where: an overview of determinants of sunbed use in Europe.

Author: Suppa M, Gandini S, Bulliard JL, Daxhelet M, Zamagni M, Forsea AM, Longo MI, and Del Marmol V
Subjects: Age Factors, Europe, Humans, Phenotype, Risk Factors, Sex Factors, Skin Pigmentation, Socioeconomic Factors, Risk-Taking, Skin Neoplasms etiology, Sunbathing statistics & numerical data, Ultraviolet Rays adverse effects
Abstract: Although exposure to indoor tanning has been established as a clear risk factor for skin cancer, sunbeds are still commonly used in Europe. Understanding the determinants of sunbed use in Europe is key to plan educational interventions, behavioural strategies and legislative measures, which should be tailored to subgroups with different risk profiles. Evidences show that the typical sunbed users in Europe are young-adult women, with intermediate skin type, a current employment and a medium/high socio-economic status. Typical users display sun-seeking behaviours and other risky behaviours such as smoking. Indoor tanning seems more common in northern than southern Europe. However, sunbed use remains common in fair-skinned individuals and among adolescents/pre-adolescents. Commonly reported reasons for sunbed use in Europe include aesthetic motives (i.e. looking attractive), the pursue of a prevacation tan, the influence of peers/parents engaging in the same habit, and the treatment of health conditions. The most commonly reported places to get an artificial tan in Europe are tanning studios and beauty salons. However, sunbeds are also available in sport venues, such as swimming pools and gyms, hotels and private houses. All these factors should be taken into account when planning educational, behavioural and legislative interventions to reduce the popularity of artificial tanning in Europe., (© 2019 European Academy of Dermatology and Venereology.)
Published: 2019
Full Text: View/download PDF

48. Sunbed use legislation in Europe: assessment of current status.

Author: Longo MI, Bulliard JL, Correia O, Maier H, Magnússon SM, Konno P, Goad N, Duarte AF, Oláh J, Nilsen LTN, Peris K, Karls R, Forsea AM, and Del Marmol V
Subjects: Adolescent, Advertising legislation & jurisprudence, Child, Europe, Humans, Law Enforcement, Surveys and Questionnaires, Ultraviolet Rays adverse effects, Beauty Culture instrumentation, Beauty Culture legislation & jurisprudence, Minors legislation & jurisprudence, Skin Neoplasms prevention & control, Sunbathing legislation & jurisprudence
Abstract: Background: The use of UV-emitting tanning devices for cosmetic purposes is associated with an increased risk of melanoma and non-melanoma skin cancer. Young women are the most frequent users, therefore, there is an increasing concern about the regulation of sunbed use., Objective: The primary objective is to assess the current legislation on sunbed use among European countries., Methods: We developed a 30-item questionnaire to gather the most relevant information about sunbed use legislation. The questionnaire was sent to Euromelanoma coordinators and to designated coordinators out of the Euromelanoma network., Results: We obtained a response rate of 64%. More than 25% of the countries did not report any specific legislation. Roughly one-third of the countries does not have a restriction for minors. Even in countries with a specific legislation, a lack or insufficient enforcement of age limit was observed in up to 100% of the inspections based on the PROSAFE report from 2012. Self-tanning devices were reported in 50%, and almost 40% of countries do not require supervision of use. Although a warning display is required in 77% of cases, a signed informed consent is not required in 80%. In the vast majority of cases, the number of licensed or closed tanning centres is unknown., Conclusions: Despite the evidence of its harmful effects, and its frequent use by young people, many of whom are at high risk of skin cancer because of fair skin, a significant number of European countries lack a specific legislation on tanning devices. In order to limit the access of young people to sunbeds, a more strictly enforced regulation is needed, as well as regulation regarding advertisement, and location of tanning centres, in addition to health promotion campaigns that target the vulnerable population of young women seeking its use for improved cosmesis., (© 2019 European Academy of Dermatology and Venereology.)
Published: 2019
Full Text: View/download PDF

49. The impact of dermoscopy on melanoma detection in the practice of dermatologists in Europe: results of a pan-European survey.

Author: Forsea AM, Tschandl P, Zalaudek I, Del Marmol V, Soyer HP, Argenziano G, and Geller AC
Subjects: Adult, Europe, Female, Humans, Male, Middle Aged, Dermatologists, Dermoscopy statistics & numerical data, Melanoma diagnosis, Skin Neoplasms diagnosis
Abstract: Background: Dermoscopy is a widely used technique that can increase the sensitivity and specificity of melanoma detection. Information is lacking on the impact of dermoscopy use on the detection of melanoma in the real-life practice of European dermatologists., Objective: To identify factors that influence the benefit of using dermoscopy for increasing melanoma detection and lowering the number of unnecessary biopsies in the practice of European dermatologists., Methods: We conducted a survey of dermatologists registered in 32 European countries regarding the following: the demographic and practice characteristics, dermoscopy training and use, opinions on dermoscopy and the self-estimated impact of dermoscopy use on the number of melanomas detected and the number of unnecessary biopsies performed in practice., Results: Valid answers were collected for 7480 respondents, of which 6602 reported using dermoscopy. Eighty-six per cent of dermoscopy users reported that dermoscopy increased the numbers of melanomas they detected, and 70% reported that dermoscopy decreased the number of unnecessary biopsies of benign lesions they performed. The dermatologists reporting these benefits were more likely to have received dermoscopy training during residency, to use dermoscopy frequently and intensively, and to use digital dermoscopy systems and pattern analysis compared to dermatologists who did not perceive any benefit of dermoscopy for the melanoma recognition in their practice., Conclusions: Improving dermoscopy training, especially during residency and increasing access to digital dermoscopy equipment are important paths to enhance the benefit of dermoscopy for melanoma detection in the practice of European dermatologists., (© 2017 European Academy of Dermatology and Venereology.)
Published: 2017
Full Text: View/download PDF

50. Factors driving the use of dermoscopy in Europe: a pan-European survey.

Author: Forsea AM, Tschandl P, Del Marmol V, Zalaudek I, Soyer HP, Geller AC, and Argenziano G
Subjects: Adult, Attitude of Health Personnel, Attitude to Health, Dermatologists psychology, Europe, Female, Humans, Male, Middle Aged, Dermoscopy statistics & numerical data, Skin Diseases diagnostic imaging
Abstract: Background: When used correctly, dermoscopy is an essential tool for helping clinicians in the diagnosis of skin diseases and the early detection of skin cancers. Despite its proven benefits, there is a lack of data about how European dermatologists use dermoscopy in everyday practice., Objectives: To identify the motivations, obstacles and modifiable factors influencing the use of dermoscopy in daily dermatology practice across Europe., Methods: All registered dermatologists in 32 European countries were invited to complete an online survey of 20 questions regarding demographic and practice characteristics, dermoscopy training and self-confidence in dermoscopic skills, patterns of dermoscopy use, reasons for not using dermoscopy and attitudes relating to dermoscopy utility., Results: We collected 7480 valid answers, of which 89% reported use of dermoscopy. The main reasons for not using dermoscopy were lack of equipment (58% of nonusers) and lack of training (42%). Dermoscopy training during residency was reported by 41% of dermoscopy users and by 12% of nonusers (P < 0·001). Dermatologists working in public hospitals were the least likely to use dermoscopy. High use of dermoscopy across the spectrum of skin diseases was reported by 62% of dermoscopy users and was associated with dermoscopy training during residency, the use of polarized light and digital dermoscopy devices, longer dermoscopy practice, younger age and female gender., Conclusions: Expanding access to dermoscopy equipment, especially in public healthcare facilities and establishing dermoscopy training during dermatology residency would further enhance the substantially high dermoscopy use across European countries., (© 2016 British Association of Dermatologists.)
Published: 2016
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

50 results on '"Forsea, A.-M."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources